Updated on 2022/12/01

写真a

 
UEKI Yushi
 
Organization
University Medical and Dental Hospital Otolaryngology, Head and Neck Surgery Assistant Professor
Title
Assistant Professor
External link

Degree

  • 学士(医学) ( 2003.3   新潟大学 )

Research Areas

  • Life Science / Otorhinolaryngology

Research History (researchmap)

  • 新潟大学医歯学総合病院 耳鼻咽喉科・頭頚部外科   特任助教

    2019.1

      More details

  • 癌研究会有明病院 頭頚科

    2009.4 - 2011.3

      More details

  • 新潟大学医学部 耳鼻咽喉科・頭頚部外科

    2003.4

      More details

Research History

  • Niigata University   Otolaryngology, Head and Neck Surgery, University Medical and Dental Hospital   Assistant Professor

    2022.4

  • Niigata University   University Medical and Dental Hospital Otolaryngology, Head and Neck Surgery   Specially Appointed Assistant Professor

    2019.1 - 2022.3

 

Papers

  • Actual prevalence of hypoparathyroidism after total thyroidectomy: a health insurance claims-database study. International journal

    Takeshi Takahashi, Keisuke Yamazaki, Ryusuke Shodo, Yushi Ueki, Arata Horii

    Endocrine   78 ( 1 )   151 - 158   2022.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Persistent hypoparathyroidism (hypoPT) is a major complication of total thyroidectomy. Nonetheless, previous reports may have underestimated the prevalence of hypoPT due to patient selection bias. We aimed to estimate the actual prevalence of persistent hypoPT after total thyroidectomy and to find predictive factors for postoperative hypoPT. METHODS: This study retrospectively reviewed data from a health insurance claims-based database provided by the Japan Medical Data Center Co., Ltd. From 2009 to 2019, 2388 patients who underwent total thyroidectomy were identified using the medical procedure codes. Persistent hypoPT was defined as the prescription of active vitamin D supplements for >1 year postoperatively and the assignment of hypoPT codes. The prevalence of persistent hypoPT was estimated at two different levels: minimum and maximum estimations with or without postoperative osteoporosis and/or renal failure codes. Correlates for persistent hypoPT were investigated among several demographic and clinical variables. RESULTS: Of the 2388 patients, 1752 (73.4%) were women with a mean age of 45 years. The types of diseases were: benign thyroid disease (n = 235), malignant thyroid tumors (n = 1570), Graves ' disease (n = 558), and malignancy combined with Graves' disease (n = 25). The minimum and the maximum estimation of the prevalence of persistent hypoPT were 15.0 and 20.3%, respectively. Multivariate logistic regression analysis showed that the malignant tumor (odds ratio, 1.8) independently correlated with persistent hypoPT. CONCLUSIONS: The prevalence of persistent hypoPT after total thyroidectomy estimated by the claims-based database was higher than previously recognized. Comprehensive attempts to preserve parathyroid function, especially in malignant diseases, are essential.

    DOI: 10.1007/s12020-022-03153-1

    PubMed

    researchmap

  • Head and neck cancer fungating wounds: a novel odour transferrer. International journal

    Hisayuki Ota, Yushi Ueki, Keisuke Yamazaki, Ryusuke Shodo, Takeshi Takahashi, Yusuke Yokoyama, Arata Horii

    BMJ supportive & palliative care   2022.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: The management for malodour of malignant fungating wounds (MFWs) in head and neck cancer (HNC) is unestablished. We evaluated the effects of a novel odour transferrer on malodour generated by MFWs in patients with HNC. METHODS: A spray-type odour transferrer approved by the Japanese government for safe use in humans produces a good scent by binding to bad odour. The odour of MFWs in 13 patients with HNC was scored by 37 medical staff and the patients' families using an odour scale ranging from 0 to 4 before and 1 week after application of the odour transferrer. RESULTS: The odour score marked by all investigators (n=37), nurses (n=21) and doctors (n=11) decreased significantly (p<0.01). The odour score decreased by more than 2 points for 73% of all investigators after odour transferrer application. CONCLUSION: This novel odour transferrer functions as an effective deodorant for MFWs in patients with HNC. It can be used by non-medical staff and may benefit patients with bad odours arising from MFWs as well as their families and medical staff.

    DOI: 10.1136/spcare-2022-003824

    PubMed

    researchmap

  • Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma. International journal

    Daisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, Satoshi Kano, Yoshitaka Honma, Hideaki Hirai, Natsuki Saigusa, Kohei Akazawa, Kaori Tani, Hiroya Ojiri, Kiyoaki Tsukahara, Hiroyuki Ozawa, Kenji Okami, Takahito Kondo, Takafumi Togashi, Chihiro Fushimi, Tomotaka Shimura, Akira Shimizu, Isaku Okamoto, Takuro Okada, Yorihisa Imanishi, Yoshihiro Watanabe, Kuninori Otsuka, Akihiro Sakai, Koji Ebisumoto, Yuichiro Sato, Keisuke Yamazaki, Yushi Ueki, Toyoyuki Hanazawa, Yuki Saito, Mizuo Ando, Takashi Matsuki, Masato Nakaguro, Yukiko Sato, Makoto Urano, Yoshitaka Utsumi, Shinji Kohsaka, Takashi Saotome, Yuichiro Tada

    Therapeutic advances in medical oncology   14   17588359221119538 - 17588359221119538   2022

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent or metastatic (LA/RM) salivary duct carcinoma (SDC) have been reported in prospective studies. However, the survival benefit of these therapies to conventional therapy remains controversial, and whether HER2-targeted therapy or ADT should be chosen in HER2- and androgen receptor (AR)-positive SDC patients remains unknown. Methods: Overall, 323 LA/RM SDC patients treated at seven institutions between August 1992 and June 2020 were retrospectively enrolled. The primary aim was to analyze the effect of HER2-targeted therapy and ADT on overall survival from the diagnosis of LA/RM disease to death from any cause (OS1). The secondary indicators included the overall response rate (ORR), clinical benefit rate (CBR), overall survival from therapy initiation for LA/RM disease (OS2), progression-free survival (PFS), time to second progression (PFS2), duration of response (DoR), and duration of clinical benefit (DoCB) of HER2-targeted therapy or ADT as first-line therapy for HER2-positive/AR-positive SDC. Results: Patients treated with HER2-targeted therapy or ADT had longer OS1 than those treated without these therapies (Median OS1: historical control, 21.6 months; HER2-targeted therapy, 50.6 months; ADT, 32.8 months; HER2-targeted therapy followed by ADT, 42.4 months; and ADT followed by HER2-targeted therapy, 45.2 months, p < 0.001). Among HER2-positive/AR-positive SDC patients, although HER2-targeted therapy had better ORR, CBR, and PFS than those of ADT as first-line therapy, we found no significant differences between HER2-targeted therapy and ADT regarding OS2, PFS2, DoR, and DoCB. Conclusion: Patients treated with HER2-targeted therapy and ADT showed longer survival in LA/RM SDC. HER2-targeted therapy can be recommended prior to ADT for HER2-positive/AR-positive SDC. It is warranted to establish a biomarker that could predict the efficacy of clinical benefit or better response in ADT.

    DOI: 10.1177/17588359221119538

    PubMed

    researchmap

  • Graves' disease in children: an enlarged goitre causes severe tracheal stenosis. International journal

    Shota Hiroshima, Yushi Ueki, Keisuke Yamazaki, Keisuke Nagasaki

    BMJ case reports   14 ( 11 )   2021.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1136/bcr-2021-246906

    PubMed

    researchmap

  • Comparison of Autofluorescence With Near-Infrared Fluorescence Imaging Between Primary and Secondary Hyperparathyroidism. International journal

    Mika Takeuchi, Takeshi Takahashi, Ryusuke Shodo, Hisayuki Ota, Yushi Ueki, Keisuke Yamazaki, Arata Horii

    The Laryngoscope   131 ( 6 )   E2097-E2104   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: To examine the role of autofluorescence (AF) monitoring with near-infrared fluorescence imaging (NIFI) in identifying parathyroid lesions in primary or secondary hyperparathyroidism (P-HPT or S-HPT) surgeries. STUDY DESIGN: Prospective study. METHODS: Twelve lesions each were resected from 12 and 3 patients with P-HPT and S-HPT, respectively. The mean and maximum AF intensities of the lesions normalized to that of the thyroid tissue for in situ and ex vivo preparations were compared between P-HPT and S-HPT. Subjective visual classifications of AF intensity were compared with postoperative quantitative assessments. The unevenness of AF distribution inside the lesions was assessed by determining the ratio of maximum to mean AF intensity and comparing them with the corresponding ratio for normal parathyroid glands (PGs). RESULTS: In all quantitative comparisons (in situ/ex vivo, mean, and maximum AF), AF intensities of P-HPT were stronger than those of S-PHT. The AF-positive rate in in situ subjective visual classification was higher for P-HPT (100% vs. 33%). Subjective visual classifications showed a positive correlation with AF intensities. The ratio of maximum to mean AF was higher in P-HPT and S-HPT than in normal PGs. CONCLUSIONS: For P-HPT, AF intensity in both in situ and ex vivo preparations was sufficiently high and correlated with the subjective visual classification, suggesting that NIFI may be useful for confirming P-HPT lesions. In contrast, NIFI may have only a minor role in S-HPT surgeries owing to the weak-AF of S-HPT lesions. HPT lesions show an uneven AF intensity distribution compared with normal PGs. LEVEL OF EVIDENCE: 3 Laryngoscope, 131:E2097-E2104, 2021.

    DOI: 10.1002/lary.29310

    PubMed

    researchmap

  • In Response to Regarding Near-Infrared Fluorescence Imaging in the Identification of Parathyroid Glands in Thyroidectomy. International journal

    Takeshi Takahashi, Keisuke Yamazaki, Hisayuki Ota, Ryusuke Shodo, Yushi Ueki, Arata Horii

    The Laryngoscope   131 ( 5 )   E1749   2021.5

     More details

  • 頭頸部小細胞癌の多施設調査

    松山 洋, 山崎 恵介, 植木 雄志, 正道 隆介, 高橋 剛史, 堀井 新, 塚原 清彰, 岡本 伊作, 長尾 俊孝, 北原 糺, 上村 裕和, 吉本 世一, 松本 文彦, 大上 研二, 酒井 昭博, 高野 賢一, 近藤 敦, 猪原 秀典, 江口 博孝, 折舘 伸彦, 田辺 輝彦, 中溝 宗永, 横島 一彦, 三浦 弘規, 木谷 洋輔

    頭頸部癌   47 ( 2 )   190 - 190   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • 近赤外線装置を用いた副甲状腺の自家蛍光観察pde-neoとFLUOBEAM800の比較

    高橋 剛史, 山崎 恵介, 竹内 美香, 正道 隆介, 太田 久幸, 植木 雄志, 堀井 新

    頭頸部外科   30 ( 3 )   277 - 283   2021.2

     More details

    Language:Japanese   Publisher:(NPO)日本頭頸部外科学会  

    researchmap

  • 末梢挿入型中心静脈カテーテル先端位置・合併症の左右差比較

    高橋 優人, 正道 隆介, 高橋 剛史, 植木 雄志, 山崎 恵介, 堀井 新

    日本耳鼻咽喉科学会会報   124 ( 2 )   122 - 127   2021.2

     More details

    Language:Japanese   Publisher:(一社)日本耳鼻咽喉科学会  

    末梢挿入型中心静脈カテーテル(peripherally inserted central catheter、PICC)は安全性が高く頭頸部癌の薬物療法でも用いられるが、留置側の左右差に着目した報告は少ない。PICC留置後の先端位置移動と合併症発生率の左右差について検討した。PICC留置を行った頭頸部癌145例172件を対象とし後方視的な調査を行った。留置側は右36件、左136件で、留置期間中央値は65日であった。121例137件でX線による留置時・留置後の先端位置評価が可能であった。先端位置をZone A:上大静脈下半分と右心房上部、Zone B:上大静脈上半分と左腕頭静脈合流部、Zone C:左腕頭静脈に分類し、Zone A・Bを適正位置とした。右側では留置時33件(100%)、留置後30件(91%)が適正位置であったのに対し、左側では留置時97件(93%)、留置後82件(79%)が適正位置で、留置時と留置後では有意な変化を認めた(p=0.001)。そのほかの合併症発生率に左右差は認めなかった。左側からのPICC留置では上大静脈右側壁にカテーテル先端が当たり、Zone Aへの留置率が低い。さらに留置後の体位・肢位の変化により先端が移動し、適正位置であるZone A・Bに留まりにくい。不適正な先端位置は遅発性の上大静脈壁損傷や血栓症を招くため、右側からのPICC留置が望ましいと考えられた。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01099&link_issn=&doc_id=20210226330006&doc_link_id=10.3950%2Fjibiinkoka.124.122&url=https%3A%2F%2Fdoi.org%2F10.3950%2Fjibiinkoka.124.122&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • Treatment Outcome of External Auditory Canal Carcinoma: The Utility of Lateral Temporal Bone Resection. International journal

    Kohei Saijo, Yushi Ueki, Ryoko Tanaka, Yusuke Yokoyama, Jo Omata, Takeshi Takahashi, Hisayuki Ota, Ryusuke Shodo, Keisuke Yamazaki, Takafumi Togashi, Ryuichi Okabe, Hiroshi Matsuyama, Kohei Honda, Yuichiro Sato, Yuka Morita, Kuniyuki Takahashi, Arata Horii

    Frontiers in surgery   8   708245 - 708245   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We examined the role of lateral temporal bone resection (LTBR) in the treatment of external ear canal (EAC) carcinoma between 2007 and 2018. The estimated 3-year disease-free survival (DFS) and disease-specific survival (DSS) according to the tumor stage and treatments were investigated in 36 patients with EAC squamous cell carcinoma. T stage classification according to the University of Pittsburgh staging system was as follows: 14 patients in T1, four patients in T2, nine patients in T3, and nine patients in T4. The 3-year DFS rate was 77.4% for T1 tumors, 100% for T2, 44.4% for T3 tumors, and 11.1% for T4 tumors (p < 001). The 3-year DSS rate was 100% for T1/T2 tumors, 87.5% for T3 tumors, and 11.1% for T4 tumors (p < 0.01). T1/T2 patients received mostly LTBR. Among nine T3 tumors, five patients (56%) received LTBR combined with preoperative chemotherapy and/or postoperative radiation (RT). Four of them had negative surgical margin and survived with no evidence of disease. The DFS of T3 patients who underwent concurrent chemoradiotherapy and LTBR was 0 and 80%, respectively (p = 0.048). For T1/T2 tumors, surgery achieved an excellent outcome. For T3 tumors, LTBR achieved negative surgical margin and showed good survival when combined with preoperative chemotherapy and/or postoperative RT. In contrast, the prognosis of T3 patients who could not undergo surgery was as poor as that of T4 patients. Therefore, in addition to subtotal temporal bone resection, LTBR-based treatment strategy may be a treatment option for limited cases of T3 patients.

    DOI: 10.3389/fsurg.2021.708245

    PubMed

    researchmap

  • Predicting Cervical Lymph Node Metastasis Following Endoscopic Surgery in Superficial Head and Neck Carcinoma. International journal

    Ryuichi Okabe, Yushi Ueki, Riuko Ohashi, Manabu Takeuchi, Satoru Hashimoto, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Hiroshi Matsuyama, Hajime Umezu, Shuji Terai, Yoichi Ajioka, Arata Horii

    Frontiers in surgery   8   813260 - 813260   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Early detection of head and neck carcinoma (HNC) as superficial HNC (SHNC) identified using recently developed optical techniques, such as magnifying endoscopy and narrow-band imaging (NBI), in combination with endoscopic surgeries enables minimally invasive treatment with favorable outcomes for HNC. This study aimed to identify the predictive factors for the rare but important clinical issue of SHNC, namely cervical lymph node metastasis (CLNM), following endoscopic resection. METHODS: Sixty-nine patients with SHNC who underwent endoscopic resection were enrolled in the study. Clinical data, preoperative endoscopic findings, pathological findings, and treatment outcomes were retrospectively reviewed. Because the pharyngeal mucosa lacks the muscularis mucosa, we measured tumor thickness in permanent pathology as an alternative to the depth of invasion. Correlations with the occurrence of CLNM were statistically examined. RESULTS: The 5-year disease-specific survival rate was 100%. Of 69 patients, 3 (4.3%) developed CLNM. All had subepithelial but not epithelial tumors. The 0-IIa type in the macroscopic findings, type B2/B3 vessels in narrow-band imaging, tumors ≥ pathological stage T2, lymphatic invasion, positive surgical margins, and tumor thickness >1,000 μm showed significant correlations with CLNM following endoscopic resection. Furthermore, the classification of type B vessels was significantly associated with tumor thickness. CONCLUSION: The treatment outcomes following endoscopic resection for SHNC were favorable. The risk of CLNM following endoscopic resection in SHNC can be predicted by several preoperative endoscopic and postoperative pathological findings. Among them, the classification of type B vessels, which correlated with both tumor thickness and CLNM, might be a useful predictive factor.

    DOI: 10.3389/fsurg.2021.813260

    PubMed

    researchmap

  • The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy. International journal

    Natsuki Saigusa, Hideaki Hirai, Yuichiro Tada, Daisuke Kawakita, Masato Nakaguro, Kiyoaki Tsukahara, Satoshi Kano, Hiroyuki Ozawa, Takahito Kondo, Kenji Okami, Takafumi Togashi, Yukiko Sato, Makoto Urano, Manami Kajiwara, Tomotaka Shimura, Chihiro Fushimi, Akira Shimizu, Isaku Okamoto, Takuro Okada, Takayoshi Suzuki, Yorihisa Imanishi, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Yuichiro Sato, Yoshitaka Honma, Keisuke Yamazaki, Yushi Ueki, Toyoyuki Hanazawa, Yuki Saito, Hideaki Takahashi, Mizuo Ando, Shinji Kohsaka, Takashi Matsuki, Toshitaka Nagao

    Frontiers in oncology   11   779882 - 779882   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Salivary duct carcinoma (SDC) is a highly aggressive and uncommon tumor arising not only de novo but also in pleomorphic adenoma. Androgen receptor (AR)- and HER2-targeted therapy have recently been introduced for SDC as promising treatment options; however, no predictive biomarkers have yet been established. EZH2 and H3K27me3 are closely linked to the development and progression of various cancers, and EZH2 is also expected to be a desirable therapeutic target. We therefore explored the clinicopathological and prognostic implications of EZH2 and H3K27me3 in a large cohort of SDC patients, focusing on their impact on the therapeutic efficacy of AR- or HER2-targeted therapy. MATERIALS AND METHODS: The EZH2 and H3K27me3 immunohistochemical expression and EZH2 Y646 gain-of-function mutation status were examined in 226 SDCs, and the relationship with the clinicopathological factors as well as clinical outcomes were evaluated within the three groups depending on the treatment: AR-targeted (combined androgen blockade with leuprorelin acetate and bicalutamide; 89 cases), HER2-targeted (trastuzumab and docetaxel; 42 cases), and conventional therapy (112 cases). RESULTS: EZH2 and H3K27me3 were variably immunoreactive in most SDCs. A positive correlation was found between the expression of EZH2 and H3K27me3. The EZH2 expression in the SDC component was significantly higher than that in the pre-existing pleomorphic adenoma component. EZH2 Y646 was not identified in any cases. EZH2-high cases more frequently had an advanced clinical stage and aggressive histological features than EZH2-low cases. An EZH2-high status in patients treated with AR-targeted therapy was associated with a significantly shorter progression-free and overall survival as well as a lower objective response rate and clinical benefit rate. In addition, a H3K27me3-high status in patients treated with AR-targeted therapy was related to a shorter overall survival. Conversely, there was no association between the EZH2 and H3K27me3 expression and the clinical outcomes in the conventional or HER2-targeted therapy groups. CONCLUSIONS: A high expression of EZH2 and H3K27me3 in SDC might be a predictor of a poor efficacy of AR-targeted therapy. Our data provide new insights into the role of EZH2 and H3K27me3 in therapeutic strategies for SDC.

    DOI: 10.3389/fonc.2021.779882

    PubMed

    researchmap

  • Treatment Outcomes and the Safety of Chemoradiotherapy With High-Dose CDDP for Elderly Patients With Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Study. International journal

    Jo Omata, Yushi Ueki, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Kohei Saijo, Hisayuki Ota, Takafumi Togashi, Yuichiro Sato, Arata Horii

    Frontiers in surgery   8   753049 - 753049   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Objective: We aimed to compare the outcomes and safety of chemoradiotherapy (CRT) between elderly and non-elderly patients with head and neck squamous cell carcinoma (HNSCC). It is difficult to assess the causal effect of age because of possible differences in general conditions among individuals. Therefore, we adjusted the background factors of elderly and non-elderly patients using propensity score matching (PSM). Methods: A total of 146 patients with HNSCC who received CRT were divided into an elderly (≥70 years, n = 35) and non-elderly group (<70 years, n = 111). Pre-treatment characteristics, including the performance status, Charlson comorbidity index, body mass index, primary site, and TNM stage were adjusted by PSM. We compared the outcomes and safety of CRT with high-dose single-agent cisplatin (CDDP) as well as outcomes following recurrence between the groups, before and after PSM. Results: The total dose of CDDP administered during CRT was significantly lower in the elderly group before PSM. However, it became comparable to the non-elderly group and adverse events did not differ between the groups following PSM, resulting in a comparable CRT completion rate. Overall-, disease specific-, and progression-free survivals of elderly patients were comparable to those of non-elderly patients following PSM. In contrast, elderly patients with recurrence could receive fewer salvage treatments than their non-elderly counterparts, resulting in worse survival. Conclusions: CRT with high-dose CDDP is safe and effective for the treatment of elderly patients with HNSCC. However, salvage treatments can be rarely conducted for elderly patients with a recurrence, considering a deterioration of their general condition.

    DOI: 10.3389/fsurg.2021.753049

    PubMed

    researchmap

  • Near-Infrared Fluorescence Imaging in the Identification of Parathyroid Glands in Thyroidectomy. Reviewed International journal

    Takeshi Takahashi, Keisuke Yamazaki, Hisayuki Ota, Ryusuke Shodo, Yushi Ueki, Arata Horii

    The Laryngoscope   131 ( 5 )   1188 - 1193   2020.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES/HYPOTHESIS: To assess the ability of near-infrared fluorescence imaging (NIFI) to identify parathyroid glands (PGs) among histologically proven PG/non-PG specimens compared with a surgeon's visual acumen, and to determine NIFI sensitivity in detecting incidentally resected PGs from thyroidectomy specimens, compared to the surgeon's visual inspection. STUDY DESIGN: Prospective study. METHODS: With mean age of 61 years, 36 patients with various thyroid diseases were enrolled. Possible PGs (n = 28) and lymph nodes (n = 32) were identified by the experienced surgeon's visual inspection. Using NIFI, 15 PGs were further identified from thyroidectomy specimens. For these 75 specimens, the surgeon's judgments (PG vs. non-PG) were recorded. Histological evaluation was performed after examining the NIFI auto-fluorescence of each specimen. RESULTS: There were no significant differences in sensitivity, specificity, positive predictive value, and negative predictive value between the surgeon's visual inspection and NIFI in identifying PGs, with values of 100%/97.1%, 85.0%/87.5%, 85.4%/87.2%, and 100%/97.2%, respectively. The sensitivity of NIFI (82.9%) for detection of PGs from thyroidectomy specimens was significantly higher than that of the surgeon's visual inspection (61.0%). False negative specimens contained bleeding/congestion and/or encapsulation by thick tissues, whereas false positive specimens contained electrocoagulated tissues. CONCLUSIONS: NIFI showed results comparable to the experienced surgeon's visual inspection in identifying PGs. This could benefit novice surgeons. NIFI may be useful for experienced surgeons to locate incidentally resected PGs within thyroidectomy specimens for auto-transplantation. Prevention of intra-gland bleeding and congestion, careful removal of thick capsules, and bloodless surgeries without electrocoagulation are important for reducing false positive and false negative results. Laryngoscope, 2020.

    DOI: 10.1002/lary.29163

    PubMed

    researchmap

  • Carotid blowout-a rare but fatal complication of endoscopic submucosal dissection of superficial hypopharyngeal carcinoma after radiotherapy. Reviewed International journal

    Ryuichi Okabe, Yushi Ueki, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Satoru Hashimoto, Arata Horii

    Auris, nasus, larynx   49 ( 1 )   152 - 156   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Endoscopic submucosal dissection (ESD) has gained wide acceptance as a minimally invasive and curative surgery for superficial head and neck carcinoma. However, the safety of ESD for superficial pharyngeal carcinoma after radiotherapy has not been elucidated. Superficial hypopharyngeal carcinoma of the left pyriform sinus developed in a 76-year-old man who had undergone concurrent chemoradiotherapy for T2N2bM0 pyriform sinus carcinoma on the opposite side 12 months before. He underwent ESD without complications. Because tumor invasion into the muscular layer was a concern, the muscular layer was partially resected with the tumor. Twelve days after discharge, he presented with a sore throat and difficulty in swallowing. Endoscopy and computed tomography revealed necrosis due to wound infection with abscess formation around the left carotid artery. The common carotid artery subsequently ruptured. Although the surgical intervention was performed, he passed away 46 days after ESD due to carotid blowout. ESD is a minimally invasive treatment for superficial head and neck carcinoma, but carotid blowout can occur in cases after radiation. Prior radiotherapy and deeper dissection into the muscular layer may hamper wound epithelization, resulting in infection-induced necrosis and carotid blowout. Diligent monitoring of wound healing is essential in patients who have previously undergone irradiation.

    DOI: 10.1016/j.anl.2020.08.020

    PubMed

    researchmap

  • Sarcopenia predicts a poor treatment outcome in patients with head and neck squamous cell carcinoma receiving concurrent chemoradiotherapy. Reviewed International journal

    Ryusuke Shodo, Keisuke Yamazaki, Yushi Ueki, Takeshi Takahashi, Arata Horii

    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery   278 ( 6 )   2001 - 2009   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Sarcopenia, defined as a decrease in the skeletal muscle mass and its function, is associated with a poor clinical outcome in several malignancies. We aimed to examine whether sarcopenia can be a predictor of incompletion of concurrent chemoradiotherapy (CCRT) and survival for head and neck cancer (HNC) patients. METHODS: Forty-one male HNC patients who received CCRT were enrolled in the study. Cross-sectional muscle areas at the third lumbar vertebral level were normalized by the squared height of the patients and were termed the lumbar skeletal muscle index (LSMI, cm2/m2), a marker of sarcopenia. Patients were divided into high (30/41, 73%) and low (11/41, 27%) LSMI groups. The LSMI cut-off value was set at 39.7 cm2/m2 based on a receiver operating characteristic curve for incompletion of CCRT. The groups were compared for survival rate by the Kaplan-Meier method. Factors predicting incompletion of CCRT were investigated among several variables. RESULTS: Multivariate analysis showed that a pre-treatment low LSMI (P = 0.033) and age over 70 years (P = 0.023) were the only significant predictors for incompletion of CCRT. The 2-year disease-specific survival (DSS) rate was significantly lower in the low LSMI group (61%) than in the high LSMI group (97%, P = 0.012), whereas there were no differences in the DSS rate between the low and high body mass index groups. CONCLUSION: The prevalence of sarcopenia in HNC patients receiving CCRT was 27%. Its presence before treatment was a significant predictor of incomplete CCRT and poor DSS rate in HNC patients.

    DOI: 10.1007/s00405-020-06273-4

    PubMed

    researchmap

  • Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score. Reviewed International journal

    Yushi Ueki, Takeshi Takahashi, Hisayuki Ota, Ryusuke Shodo, Keisuke Yamazaki, Arata Horii

    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery   277 ( 8 )   2341 - 2347   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: The importance of nivolumab for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is rapidly increasing. However, prognostic factors have not been determined for predicting treatment outcome. We aimed to investigate the prognostic factors in R/M HNSCC patients treated with nivolumab. METHODS: This retrospective study included 42 patients with R/M HNSCC who received nivolumab therapy. Correlations of overall survival (OS) with various patient characteristics including age, recurrent/metastatic site, performance status (PS), programmed death-ligand 1 positivity, body mass index, neutrophil-to-lymphocyte ratio, modified Glasgow prognostic score (mGPS), previous cetuximab administration, and immune-related adverse events were investigated. RESULTS: The overall response rate and disease control rate were 16.7% and 45.2%, respectively. Estimated 1-year OS and progression-free survival (PFS) were 56.4% and 24.5%, respectively. Multivariate analysis revealed that PS = 2 (hazard ratio 0.147; 95% CI 0.041-0.527; p = 0.003) and mGPS = 2 (hazard ratio 0.188; 95% CI, 0.057-0.620; p = 0.006) were independent predictors of poor OS. Given that the PS and mGPS were independent prognostic factors, we classified patients into three groups according to PS and mGPS: Group 1, both PS and mGPS were 0 or 1 (n = 30); Group 2, either PS or mGPS was 2 (n = 9); Group 3, both PS and mGPS were 2 (n = 3). The OS curves were significantly stratified among the three groups. CONCLUSION: The combination of PS and mGPS accurately predicted OS after nivolumab therapy. Preventive intervention to maintain general condition without simultaneously exceeding level 2 of PS and mGPS might be important for improving treatment outcomes of nivolumab.

    DOI: 10.1007/s00405-020-05945-5

    PubMed

    researchmap

  • Role of programmed death-ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma. Reviewed International journal

    Yushi Ueki, Takeshi Takahashi, Hisayuki Ota, Ryusuke Shodo, Keisuke Yamazaki, Arata Horii

    Head & neck   42 ( 11 )   3275 - 3281   2020.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: It was reported that treatment outcomes of the salvage chemotherapy (SCT) following nivolumab are fairly good compared with those of nivolumab itself. However, predictive factors of SCT for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) were not determined. METHODS: Twenty-one R/M HNSCC patients received SCT following nivolumab. The treatment outcome and predictive factors for the favorable response to SCT were investigated. RESULTS: The objective response rate (ORR) and the disease control rate of SCT were 52.4% and 81.0%, respectively. The median progression-free survival and the median overall survival time were 5.4 and 12.9 months, respectively. Patients with positive programmed death-ligand 1 (PD-L1) expression showed greater tumor shrinkage evaluated by the response evaluation criteria in solid tumors and higher ORR than those with negative PD-L1 expression. CONCLUSIONS: Treatment outcome of SCT following nivolumab in R/M HNSCC was favorable. PD-L1 expression may be a predictive factor of SCT.

    DOI: 10.1002/hed.26374

    PubMed

    researchmap

  • 頭頸部皮膚自壊悪性腫瘍におけるにおい対策 デオマジック(商標名)の効果

    山崎 恵介, 太田 久幸, 高橋 剛史, 正道 隆介, 植木 雄志, 堀井 新

    頭頸部癌   46 ( 2 )   167 - 167   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma: Proposal of a Novel Histologic Risk Stratification Model. Reviewed International journal

    Masato Nakaguro, Yukiko Sato, Yuichiro Tada, Daisuke Kawakita, Hideaki Hirai, Makoto Urano, Tomotaka Shimura, Kiyoaki Tsukahara, Satoshi Kano, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Chihiro Fushimi, Akira Shimizu, Soichiro Takase, Takuro Okada, Hiroki Sato, Yorihisa Imanishi, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Takafumi Togashi, Yushi Ueki, Hisayuki Ota, Natsuki Saigusa, Hideaki Takahashi, Mizuo Ando, Toyoyuki Hanazawa, Toshitaka Nagao

    The American journal of surgical pathology   44 ( 4 )   526 - 535   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Salivary duct carcinoma (SDC) is a rare, aggressive malignancy that histologically resembles high-grade mammary duct carcinoma. Because of the rarity of this entity, data verifying the association between histologic features and patient survival are limited. We conducted a comprehensive histologic review of 151 SDC cases and performed an analysis of the association between various histomorphologic parameters and the clinical outcome with the aim of developing a histologic risk stratification model that predicts the prognosis of SDC patients. A multivariate analysis revealed that prominent nuclear pleomorphism (overall survival [OS]: P=0.013; progression-free survival [PFS]: P=0.019), ≥30 mitoses/10 HPF (PFS: P=0.013), high tumor budding (OS: P=0.011; PFS: P<0.001), and high poorly differentiated clusters (OS: P<0.001; PFS: P<0.001) were independent prognostic factors. Patients with vascular invasion demonstrated a marginally significant association with shorter PFS (P=0.064) in a multivariate analysis. We proposed a 3-tier histologic risk stratification model based on the total number of positive factors among 4 prognostically relevant parameters (prominent nuclear pleomorphism, ≥30 mitoses/10 HPF, vascular invasion, and high poorly differentiated clusters). The OS and PFS of patients with low-risk (0 to 1 point) (23% of cases), intermediate-risk (2 to 3 points) (54% of cases), and high-risk (4 points) (23% of cases) tumors progressively deteriorated in this order (hazard ratio, 2.13 and 2.28, and 4.99 and 4.50, respectively; Ptrend<0.001). Our histologic risk stratification model could effectively predict patient survival and may be a useful aid to guide clinical decision-making in relation to the management of patients with SDC.

    DOI: 10.1097/PAS.0000000000001413

    PubMed

    researchmap

  • 骨転移との鑑別を要したBrown tumor合併副甲状腺癌の一例

    植木 雄志, 高橋 剛史, 太田 久幸, 正道 隆介, 山崎 恵介, 梅津 哉, 堀井 新

    日本内分泌外科学会雑誌   37 ( 1 )   55 - 59   2020.3

     More details

    Language:Japanese   Publisher:(一社)日本内分泌外科学会  

    症例は71歳女性で、血液検査にてPTH-intactが1246pg/mlと著明高値であったため当院代謝内分泌内科を紹介初診となった。頸胸腹部CT上、甲状腺左葉背側の腫瘍性病変と硬化性、溶骨性の混在した多発性骨病変が指摘され、副甲状腺癌および多発骨転移が疑われた。高カルシウム血症の補正目的にシナカルセトが開始されたが改善が得られず、手術目的に当科紹介となった。術前画像所見からは副甲状腺腫瘍と甲状腺左葉の境界が不明瞭であったことから、副甲状腺腫瘍摘出の際に甲状腺左葉も合併切除した。病理所見では線維性の被膜を有し、好酸性細胞がシート状に増殖する像を認めた。核異型は軽度であるものの、脈管侵襲を認めること、Ki-67 indexは10%でhot spotを認めることから副甲状腺癌の診断となった。骨病変に対する治療については、腰椎病変に対してのみ病的骨折予防目的に放射線治療を行い、臨床経過から副甲状腺癌にBrown tumorを合併したものと判断した。

    researchmap

  • The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma. Reviewed International journal

    Hideaki Hirai, Yuichiro Tada, Masato Nakaguro, Daisuke Kawakita, Yukiko Sato, Tomotaka Shimura, Kiyoaki Tsukahara, Satoshi Kano, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Chihiro Fushimi, Akira Shimizu, Isaku Okamoto, Soichiro Takase, Takuro Okada, Hiroki Sato, Yorihisa Imanishi, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Takafumi Togashi, Yushi Ueki, Hisayuki Ota, Natsuki Saigusa, Hideaki Takahashi, Mizuo Ando, Makoto Urano, Toyoyuki Hanazawa, Toshitaka Nagao

    Virchows Archiv : an international journal of pathology   477 ( 2 )   291 - 299   2020.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Salivary duct carcinoma (SDC) is an aggressive, uncommon tumor histologically comparable to high-grade mammary ductal carcinoma. SDCs are usually androgen receptor (AR)-positive and often HER2-positive. Recently, therapies targeting these molecules for SDC have attracted attention. Lipid metabolism changes have been described in association with biological behavior in various cancers, although no such relationship has yet been reported for SDC. We therefore analyzed the clinicopathological relevance of the immunohistochemical expression of adipophilin (ADP) and fatty acid synthase (FASN), representative lipid metabolism-related proteins, in 147 SDCs. ADP and FASN were variably immunoreactive in most SDCs (both 99.3%), and the ADP and FASN expression was negatively correlated (P = 0.014). ADP-positive (≥ 5%) SDCs more frequently exhibited a prominent nuclear pleomorphism and high-Ki-67 labeling index than those ADP-negative (P = 0.013 and 0.011, respectively). In contrast, a high FASN score, calculated by the staining proportion and intensity, (≥ 120) was correlated with the high expression of AR and FOXA1 (P < 0.001 and = 0.003, respectively). The ADP and FASN expression differed significantly among the subtypes based on biomarker immunoprofiling, as assessed by the AR, HER2, and Ki-67 status (P = 0.017 and 0.003, respectively). A multivariate analysis showed that ADP-positive expression was associated with a shorter overall and progression-free survival (P = 0.018 and 0.003, respectively). ADP was associated with an aggressive histopathology and unfavorable prognosis, and FASN may biologically interact with the AR signaling pathway in SDC. ADP may, therefore, be a new prognostic indicator and therapeutic target in SDC.

    DOI: 10.1007/s00428-020-02777-w

    PubMed

    researchmap

  • PLOD2 Is Essential to Functional Activation of Integrin β1 for Invasion/Metastasis in Head and Neck Squamous Cell Carcinomas. Reviewed International journal

    Yushi Ueki, Ken Saito, Hidekazu Iioka, Izumi Sakamoto, Yasuhiro Kanda, Masakiyo Sakaguchi, Arata Horii, Eisaku Kondo

    iScience   23 ( 2 )   100850 - 100850   2020.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Identifying the specific functional regulator of integrin family molecules in cancer cells is critical because they are directly involved in tumor invasion and metastasis. Here we report high expression of PLOD2 in oropharyngeal squamous cell carcinomas (SCCs) and its critical role as a stabilizer of integrin β1, enabling integrin β1 to initiate tumor invasion/metastasis. Integrin β1 stabilized by PLOD2-mediated hydroxylation was recruited to the plasma membrane, its functional site, and accelerated tumor cell motility, leading to tumor metastasis in vivo, whereas loss of PLOD2 expression abrogated it. In accordance with molecular analysis, examination of oropharyngeal SCC tissues from patients corroborated PLOD2 expression associated with integrin β1 at the invasive front of tumor nests. PLOD2 is thus implicated as the key regulator of integrin β1 that prominently regulates tumor invasion and metastasis, and it provides important clues engendering novel therapeutics for these intractable cancers.

    DOI: 10.1016/j.isci.2020.100850

    PubMed

    researchmap

  • The association between oral candidiasis and severity of chemoradiotherapy-induced dysphagia in head and neck cancer patients: A retrospective cohort study. Reviewed International journal

    Hirotake Saito, Ryusuke Shodo, Keisuke Yamazaki, Kouji Katsura, Yushi Ueki, Toshimichi Nakano, Tomoya Oshikane, Nobuko Yamana, Satoshi Tanabe, Satoru Utsunomiya, Atsushi Ohta, Eisuke Abe, Motoki Kaidu, Ryuta Sasamoto, Hidefumi Aoyama

    Clinical and translational radiation oncology   20   13 - 18   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier {BV}  

    Background and purpose: Concurrent chemoradiotherapy (CCRT) for head and neck cancer (HNC) is a risk factor for oral candidiasis (OC). As Candida spp. are highly virulent, we conducted a retrospective study to determine whether OC increases the severity of dysphagia related to mucositis in HNC patients. Patients and methods: We retrospectively analyzed the cases of consecutive patients with carcinomas of the oral cavity, pharynx, and larynx who underwent CCRT containing cisplatin (CDDP) at our hospital. The diagnosis of OC was based on gross mucosal appearance. We performed a multivariate analysis to determine whether OC was associated with the development of grade 3 dysphagia in the Radiation Therapy Oncology Group (RTOG) Acute Toxicity Criteria. The maximum of the daily opioid doses was compared between the patients with and without OC. Results: We identified 138 HNC patients. OC was observed in 51 patients (37%). By the time of their OC diagnosis, 19 (37%) had already developed grade 3 dysphagia. Among the 30 patients receiving antifungal therapy, 12 (40%) showed clinical deterioration. In the multivariate analysis, OC was independently associated with grade 3 dysphagia (OR 2.75; 95%CI 1.22-6.23; p = 0.015). The patients with OC required significantly higher morphine-equivalent doses of opioids (45 vs. 30 mg/day; p = 0.029). Conclusion: Candida infection causes refractory dysphagia. It is worth investigating whether antifungal prophylaxis reduces severe dysphagia related to candidiasis.

    DOI: 10.1016/j.ctro.2019.10.006

    PubMed

    researchmap

  • 唾液腺導管癌における脂質関連蛋白発現の臨床病理学的意義

    平井 秀明, 多田 雄一郎, 中黒 匡人, 川北 大介, 佐藤 由紀子, 志村 智隆, 塚原 清彰, 加納 里志, 小澤 宏之, 大上 研二, 佐藤 雄一郎, 伏見 千宙, 清水 顕, 高瀬 総一郎, 岡田 拓朗, 佐藤 宏樹, 今西 順久, 大塚 邦憲, 渡部 佳弘, 酒井 昭博, 戎本 浩史, 富樫 孝文, 植木 雄志, 太田 久幸, 三枝 奈津季, 高橋 秀聡, 安藤 瑞生, 浦野 誠, 花澤 豊行, 長尾 俊孝

    日本唾液腺学会誌   60   24 - 25   2019.11

     More details

    Language:Japanese   Publisher:日本唾液腺学会  

    researchmap

  • 頭頸部癌外来化学療法における上腕ポートと末梢挿入型中心静脈カテーテルの比較

    正道 隆介, 山崎 恵介, 植木 雄志, 岡部 隆一, 松山 洋, 本田 耕平, 堀井 新

    頭頸部外科   29 ( 2 )   123 - 128   2019.10

     More details

    Language:Japanese   Publisher:(NPO)日本頭頸部外科学会  

    再発転移頭頸部癌に対する外来化学療法の増加に伴い、安全な血管アクセスデバイス(VAD)が求められている。VADとしての末梢挿入型中心静脈カテーテル(PICC)27例と埋込型PICCである上腕ポート13例の安全性について比較した。両者に患者背景や治療内容に有意差を認めなかった。合併症発生数は上腕ポート群0例(0%、0/1,000カテーテル留置日)、PICC群8例(30%、1.8/1,000カテーテル留置日)で、上腕ポート群で有意に少なかった(p=0.037)。PICC群の合併症内訳はカテーテル閉塞4例、血栓症2例、カテーテル関連血流感染症1例、自己抜去1例であった。上腕ポートは安全なVADであり、頭頸部癌の外来化学療法において有用な選択肢と考えられた。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J04210&link_issn=&doc_id=20191115330005&doc_link_id=10.5106%2Fjjshns.29.123&url=https%3A%2F%2Fdoi.org%2F10.5106%2Fjjshns.29.123&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • バセドウ病術後に嚥下障害が遷延しANCA関連血管炎と診断した一例

    山崎 恵介, 植木 雄志, 正道 隆介, 高橋 剛史

    日本内分泌外科学会雑誌   36 ( Suppl.3 )   S339 - S339   2019.9

     More details

    Language:Japanese   Publisher:(一社)日本内分泌外科学会  

    researchmap

  • 【二次出版】ANL Secondary Publication 日本人頭頸部扁平上皮癌に対する高用量シスプラチン併用化学放射線療法の多施設共同第I/II相試験

    松山 洋, 山崎 恵介, 岡部 隆一, 植木 雄志, 正道 隆介, 尾股 丈, 佐藤 雄一郎, 太田 久幸, 高橋 剛史, 富田 雅彦, 横山 侑輔, 富樫 孝文, 青山 英史, 阿部 英輔, 西條 康夫, 勝良 剛詞, 曽我 麻里恵, 杉田 公, 松本 康男, 土田 恵美子, 堀井 新

    日本耳鼻咽喉科学会会報   122 ( 9 )   1269 - 1270   2019.9

  • 再発転移頭頸部扁平上皮癌に対するニボルマブ治療35例の検討 治療成績と予後因子

    植木 雄志, 正道 隆介, 岡部 隆一, 山崎 恵介, 松山 洋, 本田 耕平, 堀井 新

    頭頸部癌   45 ( 2 )   143 - 143   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • 皮膚自壊悪性腫瘍によるにおい対策 デオマジック(登録商標)の効果

    山崎 恵介, 太田 久幸, 正道 隆介, 植木 雄志, 岡部 隆一, 松山 洋, 本田 耕平, 堀井 新

    頭頸部癌   45 ( 2 )   240 - 240   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • 頭頸部癌再建手術症例における栄養指標の意義

    正道 隆介, 植木 雄志, 岡部 隆一, 山崎 恵介, 本田 耕平, 堀井 新

    頭頸部癌   45 ( 2 )   155 - 155   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • 頭頸部癌外来化学療法における上腕ポートと末梢挿入型中心静脈カテーテルの比較

    正道 隆介, 山崎 恵介, 植木 雄志, 岡部 隆一, 松山 洋, 本田 耕平, 堀井 新

    日本耳鼻咽喉科学会会報   122 ( 4 )   636 - 636   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本耳鼻咽喉科学会  

    researchmap

  • CDDP不適の頭頸部扁平上皮癌症例へのセツキシマブ併用放射線療法の治療成績 放射線単独療法との比較

    高橋 剛史, 植木 雄志, 正道 隆介, 富樫 孝文, 岡部 隆一, 山崎 恵介, 本田 耕平, 松山 洋, 富田 雅彦, 佐藤 雄一郎, 堀井 新

    日本耳鼻咽喉科学会会報   122 ( 4 )   635 - 635   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本耳鼻咽喉科学会  

    researchmap

  • 原発巣の特定に苦慮した甲状腺扁平上皮癌が疑われた一例

    今西 明, 安樂 匠, 三ツ間 友里恵, 矢口 雄大, 鈴木 達郎, 山田 貴穂, 曽根 博仁, 植木 雄志, 茂木 聡子, 梅津 哉, 大橋 瑠子, 佐々木 健太, 平田 哲大, 丸山 克也

    日本内分泌学会雑誌   95 ( 1 )   464 - 464   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本内分泌学会  

    researchmap

  • Nivolumabを投与した頭頸部癌10症例の臨床像について CM-141試験との比較

    松山 洋, 本田 耕平, 山崎 恵介, 岡部 隆一, 植木 雄志, 富樫 孝文, 正道 隆介, 堀井 新

    頭頸部外科   28 ( 3 )   313 - 318   2019.2

     More details

    Language:Japanese   Publisher:(NPO)日本頭頸部外科学会  

    Nivolumab(Nivo)が再発・転移頭頸部癌の全生存期間を有意に延長することが報告され、本邦では2017年3月から保険収載となった。本研究では2017年6〜10月に当院でNivoを投与した再発・転移頭頸部癌10例の臨床像に関して検討した。年齢は44〜75歳で中央値62.5歳、PSは0が7例、2が3例、Cetuximab(Cetu)暴露例は8例であった。観察期間の中央値6ヵ月における効果判定はPR3例、SD2例、PD5例であり、PS不良例や急速進行例では治療効果不良、Cetu暴露の有無やPD-L1染色の陽性・陰性と治療効果の間には相関がなかった。有害事象は許容範囲内であった。CheckMate-141試験と比較すると本研究の方がPS0の患者の割合が多く、Nivo投与期間が長い傾向にあった。今後、Nivoの適応決定や投与のタイミングに関して検討する必要があると思われた。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J04210&link_issn=&doc_id=20190312410012&doc_link_id=10.5106%2Fjjshns.28.313&url=https%3A%2F%2Fdoi.org%2F10.5106%2Fjjshns.28.313&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases. Reviewed International journal

    Makoto Urano, Hideaki Hirai, Yuichiro Tada, Daisuke Kawakita, Tomotaka Shimura, Kiyoaki Tsukahara, Satoshi Kano, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Chihiro Fushimi, Akira Shimizu, Soichiro Takase, Takuro Okada, Hiroki Sato, Yorihisa Imanishi, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Takafumi Togashi, Yushi Ueki, Hisayuki Ota, Yukiko Sato, Natsuki Saigusa, Masato Nakaguro, Toyoyuki Hanazawa, Toshitaka Nagao

    Histopathology   73 ( 6 )   943 - 952   2018.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    AIMS: Salivary duct carcinoma (SDC) is an uncommon, aggressive tumour that, histologically, resembles high-grade mammary ductal carcinoma, and is characterised by the expression of androgen receptor (AR). The androgen signalling pathway, a potential therapeutic target, can be regulated by FOXA1. This study aimed to evaluate the clinicopathological implications of FOXA1 in SDC. METHODS AND RESULTS: We examined the relationship between the immunoexpression of FOXA1 and FOXA1 mutations and clinicopathological factors, including the biomarker status and clinical outcome, in 142 SDCs. FOXA1 was expressed in 128 SDCs (90.1%); the immunoexpression was heterogeneous. SDCs with a higher FOXA1 labelling index (LI) (≥20%) more frequently showed less advanced tumors on T classification (P = 0.002). FOXA1 LI was correlated positively with the AR expression value (r = 0.430, P < 0.001). PI3K and p-mTOR positivity, and intact-PTEN, were associated with a higher FOXA1 LI. Twenty-two of 121 SDCs (18.2%) harboured FOXA1 gene mutations at the flanking regions in and around the forkhead DNA binding domain; however, the given gene mutation and the expression of FOXA1 were not significantly correlated. A multivariate analysis revealed that SDCs with a higher FOXA1 LI were associated with longer overall survival and progression-free survival (P = 0.029 and 0.016, respectively). CONCLUSIONS: In SDC, FOXA1, which may biologically interact with the AR and PI3K signalling pathways, is a putative biomarker that may be associated with a favourable prognosis. Further studies are needed to apply the findings to the development of targeted personalised therapy for patients with SDC.

    DOI: 10.1111/his.13706

    PubMed

    researchmap

  • Multicenter phase I/II study of chemoradiotherapy with high-dose CDDP for head and neck squamous cell carcinoma in Japan Reviewed

    Hiroshi Matsuyama, Keisuke Yamazaki, Ryuichi Okabe, Yushi Ueki, Ryusuke Shodo, Jo Omata, Yuichiro Sato, Hisayuki Ota, Takeshi Takahashi, Masahiko Tomita, Yusuke Yokoyama, Takafumi Togashi, Hidefumi Aoyama, Eisuke Abe, Yasuo Saijo, Kouji Katsura, Marie Soga, Tadashi Sugita, Yasuo Matsumoto, Emiko Tsuchida, Arata Horii

    Auris Nasus Larynx   45 ( 5 )   1086 - 1092   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier Ireland Ltd  

    Objective: Recent data indicated that concurrent chemoradiotherapy (CCRT) using high dose cisplatin (CDDP) is the most useful treatment for advanced head and neck squamous cell carcinoma (SCC). Regarding the dose of CDDP, 100 mg/m2 is most recommended in Western countries. However, in terms of a balance of efficacy and adverse events, appropriate dose of cytotoxic drugs such as CDDP may be different among the different ethnic groups. In this multicenter phase I/II study, we aimed to identify the optimal dose of CDDP in CCRT for patients with advanced head and neck SCC in the Japanese. Methods: Patients were eligible for inclusion if they had head and neck SCC that was treated with radical CCRT comprising whole-neck irradiation of the primary lesion and level II–IV lymph nodes on both sides. For the phase I study, a CDDP dose was 70 mg/m2 for level 0, 80 mg/m2 for level 1, and 100 mg/m2 for level 2. Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) were examined by phase I trial, by which CDDP dose for phase II was determined. The primary endpoint for the phase II was CCRT completion rate, and the secondary endpoint was full-dose-CCRT completion rate, the percentage of patients receiving a total CDDP dose of ≥200 mg/m2, response rate, and incidences of adverse events. Results: A CDDP dose of 100 mg/m2 was the MTD for phase I, and the recommended dose for phase II was 80 mg/m2. Forty-seven patients were evaluated in the phase II trial. CCRT completion rate, full-dose-CCRT rate, and the percentage of patients receiving a total CDDP dose of ≥200 mg/m2, were 93.6%, 78.7%, and 93.6%, respectively. One patient (2.1%) developed grade 2 renal dysfunction, and no patient developed febrile neutropenia or a grade 4 adverse event. Conclusion: The present phase I study indicated that a CDDP dose of 80 mg/m2 is the optimal dose in terms of safety. The phase II study revealed that CCRT completion rate, response rate, and rates of adverse events were not inferior for a CDDP dose of 80 mg/m2 as compared with a dose of 100 mg/m2, and a dose of 80 mg/m2 is therefore recommended in CCRT for the Japanese. This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR
    identification No. UMIN000010369).

    DOI: 10.1016/j.anl.2018.02.008

    Scopus

    PubMed

    researchmap

  • 多発遠隔転移を伴った副甲状腺癌の1例

    植木 雄志, 山崎 恵介, 正道 隆介, 岡部 隆一, 松山 洋, 本田 耕平, 堀井 新

    日本内分泌・甲状腺外科学会雑誌   35 ( Suppl.2 )   S332 - S332   2018.10

     More details

    Language:Japanese   Publisher:日本内分泌外科学会・日本甲状腺外科学会  

    researchmap

  • 中・下咽頭表在癌における拡大内視鏡所見と深達度の検討

    岡部 隆一, 松山 洋, 正道 隆介, 富樫 孝文, 植木 雄志, 山崎 恵介, 本田 耕平, 堀井 新

    頭頸部癌   44 ( 2 )   205 - 205   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • 下咽頭癌化学放射線治療における嚥下リハビリテーションの有用性についての検討

    山崎 恵介, 森 香織, 正道 隆介, 富樫 孝文, 植木 雄志, 岡部 隆一, 松山 洋, 本田 耕平, 堀井 新

    頭頸部癌   44 ( 2 )   151 - 151   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • 当科における再発頭頸部扁平上皮癌のCetuximab併用1次治療不応に対する2次治療の有効性と安全性の検討

    富樫 孝文, 正道 隆介, 植木 雄志, 岡部 隆一, 山崎 恵介, 本田 耕介, 松山 洋, 堀井 新

    頭頸部癌   44 ( 2 )   160 - 160   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • 頭頸部癌に対するNivolumab投与報告

    松山 洋, 本田 耕平, 山崎 恵介, 岡部 隆一, 植木 雄志, 富樫 孝文, 正道 隆介, 堀井 新

    頭頸部癌   44 ( 2 )   172 - 172   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas. Reviewed International journal

    Tomotaka Shimura, Yuichiro Tada, Hideaki Hirai, Daisuke Kawakita, Satoshi Kano, Kiyoaki Tsukahara, Akira Shimizu, Soichiro Takase, Yorihisa Imanishi, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Yukiko Sato, Chihiro Fushimi, Hideaki Takahashi, Takuro Okada, Hiroki Sato, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Takafumi Togashi, Yushi Ueki, Hisayuki Ota, Mizuo Ando, Shinji Kohsaka, Toyoyuki Hanazawa, Hideaki Chazono, Yoshiyuki Kadokura, Hitome Kobayashi, Toshitaka Nagao

    Oncotarget   9 ( 2 )   1852 - 1867   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The molecular characteristics of therapeutically-relevant targets and their clinicopathological implications in salivary duct carcinomas (SDCs) are poorly understood. We investigated the gene alterations and the immunoexpression of crucial oncogenic molecules in 151 SDCs. The mutation rates that were identified, in order of frequency, were as follows: TP53, 68%; PIK3CA, 18%; H-RAS, 16%; BRAF, 4%; and AKT1, 1.5%. PIK3CA/H-RAS/BRAF mutations were more common in de novo SDC than in SDC ex-pleomorphic adenoma. Furthermore, these mutations were mutually exclusive for HER2 overexpression/amplification. TP53 mutations were frequently detected in cases with the aberrant p53 expression, and TP53 missense and truncating mutations were associated with p53-extreme positivity and negativity, respectively. DISH analysis revealed no cases of EGFR amplification. The rates of PI3K, p-Akt, and p-mTOR positivity were 34%, 22%, and 66%, respectively; PTEN loss was observed in 47% of the cases. These expressions were correlated according to the signaling axis. Cases with PI3K negativity and PTEN loss appeared to show a lower expression of androgen receptor. In the multivariate analysis, patients with SDC harboring TP53 truncating mutations showed shorter progression-free survival. Conversely, p-Akt positivity was associated with a favorable outcome. This study might provide information that leads to advances in personized therapy for SDC.

    DOI: 10.18632/oncotarget.22927

    PubMed

    researchmap

  • Asymptomatic diffuse idiopathic skeletal hyperostosis as a potential risk for severe dysphagia following partial laryngopharyngectomy

    Ryusuke Shodo, Yuichiro Sato, Hisayuki Ota, Yushi Ueki, Arata Horii

    ACTA OTO-LARYNGOLOGICA CASE REPORTS   3 ( 1 )   29 - 33   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:TAYLOR & FRANCIS LTD  

    Diffuse idiopathic skeletal hyperostosis (DISH) is a common disease in which ossification lesions occur in the bones including the vertebrae. Dysphagia may occur in advanced cases, but there are few cases that require treatment. A 68-year-old man was diagnosed with hypopharyngeal cancer of the left pyriform sinus and asymptomatic DISH on the anterior cervical vertebrae. Due to prior history of radiation, partial laryngopharyngectomy was performed. After surgery, severe dysphagia and aspiration pneumonia occurred, and the patient needed to undergo total laryngectomy. It was determined that dysphagia was due to multiple factors, including insufficient laryngeal elevation and esophageal compression by osteophytes of DISH. Asymptomatic DISH can cause severe dysphagia after partial laryngopharyngectomy. We suggest that evaluation of the swallowing function and surgical options, including laryngeal suspension and cricopharyngeal myotomy should be considered when performing partial laryngopharyngectomy in patients with DISH, even if they demonstrated no difficulties in swallowing before treatment.

    DOI: 10.1080/23772484.2018.1477508

    Web of Science

    researchmap

  • Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification Reviewed

    Soichiro Takase, Satoshi Kano, Yuichiro Tada, Daisuke Kawakita, Tomotaka Shimura, Hideaki Hirai, Kiyoaki Tsukahara, Akira Shimizu, Yorihisa Imanishi, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Yukiko Sato, Chihiro Fushimi, Takuro Okada, Hiroki Sato, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Takafumi Togashi, Yushi Ueki, Hisayuki Ota, Toyoyuki Hanazawa, Hideaki Chazono, Robert Yoshiyuki Osamura, Toshitaka Nagao

    ONCOTARGET   8 ( 35 )   59023 - 59035   2017.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:IMPACT JOURNALS LLC  

    Salivary duct carcinoma (SDC) is an uncommon, aggressive malignant neoplasm histologically resembling high-grade mammary ductal carcinoma. SDC can arise de novo or ex pleomorphic adenoma. To clarify the correlation of biomarker immunoprofile with clinicopathological findings and clinical outcome of SDC, we conducted immunohistochemistry for EGFR, HER2, HER3, AR, CK5/6, p53, and Ki-67, along with HER2 fluorescence in situ hybridization in 151 SDCs. SDCs ex pleomorphic adenoma more commonly overexpressed EGFR, HER2, HER3, and Ki-67 than de novo SDCs (P = 0.015, &lt; 0.001, 0.045, and 0.02, respectively). In multivariate analysis, AR-and CK5/6+ were associated with shorter progression-free survival (P = 0.027 and 0.004, respectively). Moreover, patients with p53-extreme negative/positive demonstrated poorer overall survival (P = 0.007). On assessing the revised classification by the combination of biomarker expression, the percentages of each subtype were as follows: 'apocrine A' (AR+/HER2-/Ki-67-low) (24%), 'apocrine B' (AR+/HER2-/Ki-67-high) (18%), 'apocrine HER2' (AR+/HER2+) (35%), 'HER2-enriched' (AR-/HER2+) (12%), and 'double negative' (AR-/HER2-) (11%). 'Double negative' was further subclassified into 'basal-like' (EGFR and/or CK5/6+) (7%) and 'unclassified' (3%). Consequently,patients with 'apocrine A' showed a better progression-free survival than those with any other subtypes. Our revised immunoprofiling classification was valuable for predicting the survival and might be useful in personalized therapy for patients with SDC.

    DOI: 10.18632/oncotarget.19812

    Web of Science

    PubMed

    researchmap

  • 頭頸部扁平上皮癌Stage IVC症例の検討

    尾股 丈, 横山 侑輔, 高橋 剛史, 正道 隆介, 太田 久幸, 富樫 孝文, 植木 雄志, 岡部 隆一, 山崎 恵介, 松山 洋, 堀井 新, 佐藤 雄一郎, 富田 雅彦

    頭頸部癌   43 ( 2 )   215 - 215   2017.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • 当科における再発・転移頭頸部扁平上皮癌に対するセツキシマブ併用療法の有効性と問題点の検討

    富樫 孝文, 植木 雄志, 岡部 隆一, 山崎 恵介, 松山 洋

    頭頸部癌   43 ( 2 )   239 - 239   2017.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • 新潟県の頭頸部扁平上皮癌に対するCCRTの現状 県内多施設共同研究の最終報告

    松山 洋, 山崎 恵介, 岡部 隆一, 植木 雄志, 富樫 孝文, 横山 侑輔, 堀井 新, 佐藤 雄一郎, 正道 隆介, 太田 久幸, 富田 雅彦, 尾股 丈

    頭頸部癌   43 ( 2 )   186 - 186   2017.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • 上咽頭癌化学放射線療法後の補助化学療法

    横山 侑輔, 尾股 丈, 高橋 剛史, 正道 隆介, 富樫 孝文, 植木 雄志, 岡部 隆一, 山崎 恵介, 松山 洋, 堀井 新, 佐藤 雄一郎, 太田 久幸, 富田 雅彦

    頭頸部癌   43 ( 2 )   178 - 178   2017.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan Reviewed

    Daisuke Kawakita, Yuichiro Tada, Yorihisa Imanishi, Shintaro Beppu, Kiyoaki Tsukahara, Satoshi Kano, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Akira Shimizu, Yukiko Sato, Chihiro Fushimi, Soichiro Takase, Takuro Okada, Hiroki Sato, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Takafumi Togashi, Yushi Ueki, Hisayuki Ota, Tomotaka Shimura, Toyoyuki Hanazawa, Shingo Murakami, Toshitaka Nagao

    ONCOTARGET   8 ( 1 )   1083 - 1091   2017.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:IMPACT JOURNALS LLC  

    The prognostic role of modified Glasgow Prognostic Score (mGPS), neutrophil-to- lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with salivary duct carcinoma (SDC) remains unclear. We conducted a multi-institutional retrospective cohort study of 140 SDC patients. The survival impact of these hematological markers was evaluated using multivariate proportional hazard models. High mGPS (&gt;= 1) was significantly associated with worse survival (3-year overall survival (OS): 16.7% vs 66.1%, p-value=0.003; 3-year progression-free survival (PFS): 0.0% vs 27.9%, p-value&lt;0.001). Additionally, high C-reactive protein (CRP) (&gt;= 0.39 mg/dl) was significantly associated with worse survival (3-year OS: 32.1% vs 68.2%, p-value= 0.001; 3-year PFS: 7.1% vs 31.1%, p-value&lt;0.001). These associations were consistent with multivariate analysis adjusted for established prognostic factors. Although we also found significant association of high NLR (&gt;= 2.5) with OS (HR 1.80; 95% confidence interval, 1.05-3.08) in multivariate analysis, this association were inconsistent with the results of PFS. In addition, we found no significant associations of PLR with survival. In conclusion, we found that mGPS, CRP and NLR were identified as prognostic factors associated with survival in SDC patients.

    DOI: 10.18632/oncotarget.13565

    Web of Science

    PubMed

    researchmap

  • Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy. Reviewed International journal

    Yushi Ueki, Yuichiro Tada, Takafumi Togashi, Daisuke Kawakita, Toshitaka Nagao, Yuichiro Sato

    International cancer conference journal   5 ( 3 )   150 - 153   2016.7

     More details

    Language:English  

    Salivary duct carcinoma (SDC) has a poor prognosis owing to the high incidence of distant metastasis. Approximately 40 % of SDCs are positive for human epidermal growth factor receptor 2 (HER2), suggesting that anti-HER2 therapy for cases with distant metastasis may be effective. However, the pathological response of SDC metastases to anti-HER2 therapy has not been reported. A 44-year-old man was diagnosed with HER2-positive SDC of the submandibular gland with multiple distant metastases. After six cycles of trastuzumab/docetaxel therapy, the patient achieved clinical partial response for the primary tumor and complete response for the neck and distant metastases. Subsequently, the patient underwent submandibular gland resection and neck dissection. On histopathological examination, very few viable cancer cells were identified in the resected primary tumor. Unfortunately, the patient died of multiple distant metastases 12 months after initial treatment. Trastuzumab/docetaxel therapy can elicit a clinical and pathological response in HER2-positive SDC.

    DOI: 10.1007/s13691-016-0247-9

    Web of Science

    PubMed

    researchmap

  • Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients Reviewed

    Kuninori Otsuka, Yorihisa Imanishi, Yuichiro Tada, Daisuke Kawakita, Satoshi Kano, Kiyoaki Tsukahara, Akira Shimizu, Hiroyuki Ozawa, Kenji Okami, Akihiro Sakai, Yuichiro Sato, Yushi Ueki, Yukiko Sato, Toyoyuki Hanazawa, Hideaki Chazono, Kaoru Ogawa, Toshitaka Nagao

    ANNALS OF SURGICAL ONCOLOGY   23 ( 6 )   2038 - 2045   2016.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER  

    Among salivary gland malignancies, the prognosis of salivary duct carcinoma (SDC) is assumed to be the poorest. However, because of its low incidence, reliable survival estimates and prognostic factors based on a large number of patients remain to be elucidated, thereby making it impossible to standardize the optimal treatment for SDC.
    We performed this multi-institutional, retrospective analysis by collecting the clinical information of 141 patients with SDC without distant metastasis who underwent curative surgery as the initial treatment to elucidate overall survival (OS) and disease-free survival (DFS) along with their prognostic factors.
    The 3-year OS and DFS rates were 70.5 and 38.2 %, respectively. Multivariate analysis revealed that age a parts per thousand yen65 years (p &lt; 0.001) and N1 and N2 (p = 0.047 and &lt; 0.001, respectively) were independent prognostic factors for OS, whereas the primary site of the minor salivary and sublingual gland (p &lt; 0.001) and N2 (p &lt; 0.001) were those for DFS. The most common treatment failure was distant metastasis (55 patients, 39.0 %). For early parotid SDC, neither total parotidectomy in the patients with early T stage nor nerve resection in the patients without facial nerve palsy showed survival benefits.
    Advanced N stage independently affects both OS and DFS. Partial parotidectomy with facial nerve preservation could be a less invasive standard surgical procedure for parotid gland SDC in the early T stage without facial nerve palsy. Effective systemic therapy is imperative to improve DFS of SDC.

    DOI: 10.1245/s10434-015-5082-2

    Web of Science

    PubMed

    researchmap

  • CDDP+VP-16先行後放射線療法を行った頭頸部小細胞癌の4例

    松山 洋, 山崎 恵介, 岡部 隆一, 植木 雄志, 山崎 洋大, 正道 隆介, 太田 久幸, 高橋 剛史, 尾股 丈, 横山 侑輔, 堀井 新, 富樫 孝文

    頭頸部癌   42 ( 2 )   173 - 173   2016.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • 喉頭癌T3症例の治療法別治療成績の検討

    山崎 恵介, 横山 侑輔, 植木 雄志, 岡部 隆一, 松山 洋, 堀井 新

    頭頸部癌   42 ( 2 )   155 - 155   2016.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • 嗅神経芽細胞腫2症例に対する化学療法の経験

    横山 侑輔, 山崎 恵介, 尾股 丈, 高橋 剛史, 太田 久幸, 正道 隆介, 山崎 洋大, 植木 雄志, 岡部 隆一, 富樫 孝文, 松山 洋, 堀井 新

    頭頸部癌   42 ( 2 )   159 - 159   2016.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • 新潟県内頭頸部癌治療の統一と集約化への動き

    松山 洋, 山崎 恵介, 岡部 隆一, 植木 雄志, 堀井 新, 佐藤 雄一郎, 正道 隆介, 太田 久幸, 富田 雅彦, 富樫 孝文

    日本耳鼻咽喉科学会会報   119 ( 4 )   684 - 684   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本耳鼻咽喉科学会  

    researchmap

  • Toward unifying CCRT regimens for head and neck cancer in niigata prefecture: High-dose CDDP + RT

    Hiroshi Matsuyama, Yuichiro Sato, Masahiko Tomita, Keisuke Yamazaki, Ryuichi Okabe, Yushi Ueki, Takahumi Togashi, Hirotomo Yamazaki, Ryusuke Shodo, Hisayuki Ota, Takeshi Takahashi, Arata Horii

    Japanese Journal of Head and Neck Cancer   42 ( 1 )   70 - 75   2016

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Japan Society for Head and Neck Cancer  

    The Niigata Prefecture Head and Neck Malignant Tumor Registration Committee gathers data from cancer treatment centers in the region and has maintained a database of nearly all cases of malignancy during the last 25 years. Although the data are useful for cancer registration, it became clear that treatment centers had differing protocols and outcomes for radiation therapy and chemotherapy, and that the reliability of data on prognosis had decreased. Therefore, we designed the "Multicenter phase I/II study in Niigata Prefecture on high-dose CDDP + RT for head and neck squamous cell carcinoma", to examine treatment safety and effectiveness. Twelve cases were registered in phase I, and maximum tolerated dose, dose limiting toxicity, rules for reduction and termination of chemotherapy, and recommended CDDP dose for phase II were investigated. The phase II study will be started in the future. The recommended CDDP dose for that study is 80 mg/m2, and the primary endpoint is CCRT completion rate. The present study may become a model for the treatment of head and neck malignancies in the country. This report describes the current findings.

    DOI: 10.5981/jjhnc.42.70

    Scopus

    researchmap

  • A case of the relapsing polychondritis limited to the trachea Reviewed

    Kaori Mori, Kojiro Ishioka, Hirotomo Yamazaki, Yushi Ueki, Yamato Kubota, Hiroshi Matsuyama, Yutaka Yamamoto, Arata Horii, Sugata Takahashi

    Journal of Otolaryngology of Japan   118 ( 9 )   1150 - 1154   2015.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Oto-Rhino-Laryngological Society of Japan Inc.  

    A 62-year-old woman, who had dysesthesia in the throat, and polyposia the previous year, was admitted in a coma because of respiratory failure. Computed tomography scans demonstrated dilatation of the esophagus and stenosis of the trachea. After emergency intubation, extubation was not possible due to a collapsed trachea, so we performed a tracheostomy. The tracheoscopy from the stoma showed an esophagus-like trachea due to disappearance of the tracheal cartilage and the straight pattern on the membranous portion, and the lumen deformed with coughing. With the continuous dyspnea episode, the patient was diagnosed as having tracheomalacia. Anti-type II collagen antibody and pathological findings of the trachea led us to the diagnosis of Relapsing Polychondritis.

    DOI: 10.3950/jibiinkoka.118.1150

    Scopus

    PubMed

    researchmap

  • A case of the relapsing polychondritis limited to the trachea

    Kaori Mori, Kojiro Ishioka, Hirotomo Yamazaki, Yushi Ueki, Yamato Kubota, Hiroshi Matsuyama, Yutaka Yamamoto, Arata Horii, Sugata Takahashi

    Journal of Otolaryngology of Japan   118 ( 9 )   1150 - 1154   2015.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Oto-Rhino-Laryngological Society of Japan Inc.  

    A 62-year-old woman, who had dysesthesia in the throat, and polyposia the previous year, was admitted in a coma because of respiratory failure. Computed tomography scans demonstrated dilatation of the esophagus and stenosis of the trachea. After emergency intubation, extubation was not possible due to a collapsed trachea, so we performed a tracheostomy. The tracheoscopy from the stoma showed an esophagus-like trachea due to disappearance of the tracheal cartilage and the straight pattern on the membranous portion, and the lumen deformed with coughing. With the continuous dyspnea episode, the patient was diagnosed as having tracheomalacia. Anti-type II collagen antibody and pathological findings of the trachea led us to the diagnosis of Relapsing Polychondritis.

    DOI: 10.3950/jibiinkoka.118.1150

    Scopus

    PubMed

    researchmap

  • 当科における喉頭機能温存手術 オンリーワンならナンバーワン

    佐藤 雄一郎, 植木 雄志, 森 香織

    県立がんセンター新潟病院医誌   54 ( 2 )   115 - 116   2015.9

     More details

    Language:Japanese   Publisher:新潟県立がんセンター新潟病院  

    researchmap

  • 抗EGFR抗体による皮膚障害に対する予防的介入の効果についての検討

    結城 明彦, 高塚 純子, 竹之内 辰也, 森 香織, 植木 雄志, 佐藤 雄一郎, 野上 仁, 丸山 聡, 瀧井 康公

    県立がんセンター新潟病院医誌   54 ( 2 )   114 - 114   2015.9

     More details

    Language:Japanese   Publisher:新潟県立がんセンター新潟病院  

    researchmap

  • 甲状腺腫瘍にて診断された成人全身型筋線維腫症の1例

    植木 雄志, 佐藤 雄一郎, 森 香織, 正道 隆介, 畠野 宏史, 川崎 隆, 本間 慶一

    日本内分泌・甲状腺外科学会雑誌   32 ( 3 )   211 - 214   2015.9

     More details

    Language:Japanese   Publisher:日本内分泌外科学会・日本甲状腺外科学会  

    【症例】43歳男性。家族歴、既往歴に特記事項なし。20xx年2月から咳嗽あり、近医CTにて甲状腺腫瘍+多発肺転移の診断となり5月に当科紹介初診された。PET-CTでは甲状腺、頭部皮膚、両肺野に集積を認めた。頭部皮膚腫瘍を生検したが良性の血管平滑筋腫の診断であり、6月に甲状腺全摘およびD1郭清を施行した。術後病理診断では筋線維腫症であり、血小板由来成長因子受容体β(platelet-derived growth factor receptor β、PDGFRB)蛋白の過剰発現を認めることから、PDGFRB遺伝子変異を伴った内臓病変を有する成人全身型筋線維腫症例と考えられた。化学療法を施行するも、肺・膵臓などの内臓病変が増悪し、初診後8ヵ月で原病死した。【まとめ】非常に稀な成人筋線維腫症例を経験した。PDGFRB遺伝子変異が診断の決め手となったが、内臓病変を伴う全身型は予後不良で、治療法の確立が望まれる。(著者抄録)

    DOI: 10.11226/jaesjsts.32.3_211

    researchmap

  • 甲状腺手術後のEjnell法による声門開大術施行症例の検討

    山崎 恵介, 植木 雄志, 松山 洋

    日本内分泌・甲状腺外科学会雑誌   32 ( Suppl.2 )   S257 - S257   2015.9

     More details

    Language:Japanese   Publisher:日本内分泌外科学会・日本甲状腺外科学会  

    researchmap

  • A case of fatal interstitial pneumonia during treatment of radiotherapy plus cetuximab for patient with head and neck carcinoma

    Hiroshi Matsuyama, Katsuaki Asakawa, Kaori Shinbori, Ryusuke Shodo, Hirotomo Yamazaki, Yushi Ueki, Shuji Izumi, Satoru Miura, Sugata Takahashi

    International Cancer Conference Journal   4 ( 3 )   162 - 166   2015.7

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s13691-014-0191-5

    researchmap

    Other Link: http://link.springer.com/article/10.1007/s13691-014-0191-5/fulltext.html

  • 頭頸部領域に再発を繰り返した類上皮血管内皮腫の1例

    尾股 丈, 松山 洋, 正道 隆介, 山崎 洋大, 植木 雄志, 山崎 恵介, 山本 裕, 高橋 姿

    頭頸部外科   25 ( 1 )   55 - 60   2015.6

     More details

    Language:Japanese   Publisher:(NPO)日本頭頸部外科学会  

    頭頸部領域に再発を繰り返した類上皮血管内皮腫の1例を報告する。症例は40歳女性で、過去12年間に頭蓋骨左側、下顎骨左側、左耳下腺、鼻中隔左側の類上皮血管内皮腫に対して複数の医療機関で摘出術を施行され、経過観察目的に当科紹介となった。初診時は頭頸部領域に腫瘍性病変を認めなかったが、経過中に鼻中隔左側に腫瘤が出現した。生検にて類上皮血管内皮腫再発の診断となり、腫瘍切除術を施行した。腫瘍径と病理組織像から低危険度群に分類されたため、追加治療をせず経過観察を行っており、術後18ヵ月再発を認めていない。本症例では頭頸部領域の片側性再発を繰り返しており、今後も慎重な経過観察が必要と思われた。(著者抄録)

    DOI: 10.5106/jjshns.25.55

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J04210&link_issn=&doc_id=20150721380009&doc_link_id=10.5106%2Fjjshns.25.55&url=https%3A%2F%2Fdoi.org%2F10.5106%2Fjjshns.25.55&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • A case of laryngeal basaloid squamous cell carcinoma

    Ryusuke Shodo, Hiroshi Matsuyama, Hirotomo Yamazaki, Takahumi Togashi, Yushi Ueki, Ryuichi Okabe, Yutaka Yamamoto, Sugata Takahashi

    Japanese Journal of Head and Neck Cancer   41 ( 1 )   51 - 56   2015.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Japan Society for Head and Neck Cancer  

    Basaloid squamous cell carcinoma (BSCC) is a rare carcinoma with both basaloid and squamous components. We report a case of BSCC arising in the larynx. A 61-year-old man presented with hoarseness and sore throat. Laryngeal endoscopy revealed a tumor from the left laryngeal vestibule to both vocal cords, which caused paralysis of the left vocal cord. Squamous cell carcinoma (SCC) was confirmed in a biopsy specimen. Additional imaging studies confirmed a diagnosis of laryngeal cancer (supraglottic SCC, T3N2bM0, stage IV A). After preoperative chemotherapy, total laryngectomy and bilateral neck dissection were performed. Histopathological analysis of an operative specimen revealed BSCC, with extracapsular spread in metastatic lymph nodes. Despite adjuvant radiotherapy, multiple lung metastases rapidly developed. Chemotherapy with cisplatin, 5-fluorouracil, and cetuximab was temporarily effective, but metastasis later progressed quickly. BSCC is associated with a poor prognosis and high potential for distant metastasis and thus requires multidisciplinary therapy, including potent chemotherapy.

    DOI: 10.5981/jjhnc.41.51

    Scopus

    researchmap

  • 新潟県における頭頸部癌CCRTのレジメン統一への動き 高用量CDDP+RT

    松山 洋, 岡部 隆一, 富樫 孝文, 正道 隆介, 高橋 姿, 佐藤 雄一郎, 植木 雄志, 山崎 恵介, 富田 雅彦, 山崎 洋大

    頭頸部癌   41 ( 2 )   218 - 218   2015.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

  • Clinical study of skull base osteomyelitis Reviewed

    Yushi Ueki, Hiroshi Matsuyama, Yuka Morita, Kuniyuki Takahashi, Yutaka Yamamoto, Sugata Takahashi

    Journal of Otolaryngology of Japan   118 ( 1 )   40 - 45   2015.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Oto-Rhino-Laryngological Society of Japan Inc.  

    Typical osteomyelitis is reportedly caused by Pseudomonous aeruginosa in elderly diabetic patients after malignant external otitis. Recently, complications have arisen due to the emergence of atypical osteomyelitis. We have experiensed 5 cases of skull base osteomyelitis at our hospital. All patients were male with a mean age of 75.2 years. Four patients had diabetes. Regarding the clinical and radiographic findings, patients 1, 2, and 3 had typical osteomyelitis after malignant external otitis, whereas patients 4 and 5 had atypical osteomyelitis without temporal bone findings. Sample culturing revealed Pseudomonas aeruginosa in 4 cases and Aspergillus in one. Intravenous antibiotics were administered to all patients. Two patients responded positively and survived, while 3 died. Typical osteomyelitis is reportedly caused by P. aeruginosa in elderly diabetic patients after malignant external otitis. Recently, complications have arisen due to the emergence of atypical osteomyelitis. The prognosis of skull base osteomyelitis is still poor in Japan. Early diagnosis and long-term antibiotic administration is required to improve outcome.

    DOI: 10.3950/jibiinkoka.118.40

    Scopus

    PubMed

    researchmap

  • Clinical study of skull base osteomyelitis

    Yushi Ueki, Hiroshi Matsuyama, Yuka Morita, Kuniyuki Takahashi, Yutaka Yamamoto, Sugata Takahashi

    Journal of Otolaryngology of Japan   118 ( 1 )   40 - 45   2015.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Oto-Rhino-Laryngological Society of Japan Inc.  

    Typical osteomyelitis is reportedly caused by Pseudomonous aeruginosa in elderly diabetic patients after malignant external otitis. Recently, complications have arisen due to the emergence of atypical osteomyelitis. We have experiensed 5 cases of skull base osteomyelitis at our hospital. All patients were male with a mean age of 75.2 years. Four patients had diabetes. Regarding the clinical and radiographic findings, patients 1, 2, and 3 had typical osteomyelitis after malignant external otitis, whereas patients 4 and 5 had atypical osteomyelitis without temporal bone findings. Sample culturing revealed Pseudomonas aeruginosa in 4 cases and Aspergillus in one. Intravenous antibiotics were administered to all patients. Two patients responded positively and survived, while 3 died. Typical osteomyelitis is reportedly caused by P. aeruginosa in elderly diabetic patients after malignant external otitis. Recently, complications have arisen due to the emergence of atypical osteomyelitis. The prognosis of skull base osteomyelitis is still poor in Japan. Early diagnosis and long-term antibiotic administration is required to improve outcome.

    DOI: 10.3950/jibiinkoka.118.40

    Scopus

    PubMed

    researchmap

  • A case of an elderly patient of hypopharyngeal carcinoma developed thrombocytopenia during radiotherapy with cetuximab

    Yushi Ueki, Meiko Kanemaru, Ryusuke Shodo, Yutaka Yamamoto, Sugata Takahashi

    Practica Oto-Rhino-Laryngologica   108 ( 1 )   63 - 69   2015

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Society of Practical Otolaryngology  

    We present herein an 85-year-old patient with advanced hypopharyngeal carcinoma who developed thrombocytopenia during treatment with cetuximab plus radiotherapy. He had a medical history of diabetes mellitus and atrial fibrillation and was taking 3.5 mg of oral warfarin per day. At the time when the third dose of cetuximab was administered, the patient experienced a high-grade fever - thought to be an infusion reaction - followed by thrombocytopenia, which improved with platelet transfusion. After radiotherapy was finished, a hematoma was observed in the iliopsoas muscle on a CT scan. The prothrombin time-international normalized ratio (PT-INR) was elevated to an extremely high level of &gt
    8.0, which caused by warfarin. Thrombocytopenia owing to cetuximab is a very rare but adverse event that may occur severely in elderly patients. Therefore, it is necessary to choose the treatment carefully for them. In addition, patients with carcinoma receiving anti-coagulant therapy should be assessed for risk factors and frequently monitored for blood coagulation during anti-cancer treatment.

    DOI: 10.5631/jibirin.108.63

    Scopus

    researchmap

  • 創部での用手的誘導による経口気管挿管で気道確保に成功した穿通性頸部損傷の1例

    小林 聡, 廣瀬 保夫, 佐藤 由紀, 若生 康一, 植木 雄志, 渡辺 順, 橋本 茂久

    救急医学   38 ( 9 )   1108 - 1110   2014.9

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    症例は40代の男性で、入所中の施設にて全身痙攣発作を起こして転倒し、顔面から窓ガラスに突っ込み受傷し、直ちに救急搬送された。受診時検査所見よりzone IIの鋭的頸部気道損傷と診断し、経口的に気管挿管を行い、助手が創部で用手的にチューブを誘導したところ気道確保に成功した。気道確保後は循環動態が安定し、造影CTにて活動性の出血が示唆されたため、上甲状腺動脈、前頸静脈などを結紮止血した。次いで創部の尾側に気管切開を造設し、気管チューブを移動し、気管損傷部の浮腫が著しく一期的な修復は気管狭窄のリスクが高いと考え、開放創断端と皮膚を縫合し確実な気管皮膚瘻を作成し手術を終了した。その後の経過は良好で、第7病日に気管皮膚瘻を閉鎖後、気道を再建し、第33病日に退院となった。

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2015007202

  • 副甲状腺癌の一例

    横山 侑輔, 高橋 剛史, 植木 雄志, 山崎 恵介, 渡辺 順, 橋本 茂久

    新潟市民病院医誌   35 ( 1 )   48 - 52   2014.9

     More details

    Language:Japanese   Publisher:新潟市民病院  

    症例は84歳の女性で、右側胸部痛を主訴に当院救急外来を受診し、高カルシウム血症、腎機能低下を認め内分泌内科に緊急入院となった。原因検索のため、血液検査、超音波検査、単純CTを施行、甲状腺左葉下極に接した石灰化を伴う20mm大の腫瘤と、i-PTHの高値を認めた。さらに副甲状腺シンチグラムで異常集積がみられ、原発性副甲状腺機能亢進症と診断した。保存的治療をおこなったが、高カルシウム血症及び腎機能が徐々に増悪したため、手術目的に当科紹介となった。全身麻酔下に副甲状腺腫瘍摘出術を施行し、術中所見で周囲への浸潤は認めず、迅速病理診断は腺腫であったが、最終的な永久病理診断は副甲状腺癌となった。副甲状腺癌は非常に稀な疾患であり、術前診断が困難な事も多い。本例も手術後に診断が確定したが、術前から副甲状腺癌に特徴的な症状を念頭に置き治療にあたる必要があると思われた。(著者抄録)

    researchmap

  • 顎下腺原発唾液腺導管癌4症例の検討

    植木 雄志, 渡辺 順, 橋本 茂久, 高橋 姿

    頭頸部外科   23 ( 3 )   403 - 408   2014.2

     More details

    Language:Japanese   Publisher:(NPO)日本頭頸部外科学会  

    唾液腺導管癌(salivary duct carcinoma、以下SDC)の中でも顎下腺原発はまれである。今回顎下腺原発SDC 4例につき検討を行った。治療前の病期分類はstage Iが1例、stage IIが2例、stage IVaが1例であった。術前細胞診断で悪性を疑いえたのは1例のみで、術中迅速診断でSDCの疑いが1例、他の3例は悪性の診断であった。HER-2の過剰発現が3例にみられた。全例で頸部郭清術に加え術後照射が行われたが、3例で遠隔転移をきたし、2例は原病死した。SDCは集学的治療を行ってもなお予後不良の疾患であるが、HER-2の過剰発現が高頻度にみられることから、Trastuzumabなどの分子標的薬剤による新しい治療法の確立が期待される。(著者抄録)

    DOI: 10.5106/jjshns.23.403

    CiNii Article

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2014224602

  • Therapeutic Outcome After Resection of Pulmonary Metastasis from Head and Neck Carcinomas Reviewed

    Keisuke Yamazaki, Ryusuke Shodo, Yushi Ueki, Hiroshi Matsuyama, Sugata Takahashi

    Indian Journal of Otolaryngology and Head and Neck Surgery   67 ( 1 )   124 - 128   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer India  

    Hematogenous metastasis is the most common form of metastasis in head and neck cancer, and reports have described successful resection of pulmonary metastases of such cancers. We report treatment outcomes after surgical resection of pulmonary metastases of head and neck cancer and identify prognostic factors. This clinicopathologic study investigated the clinical records of 16 patients with pulmonary metastases of head and neck cancer (excepting cases of thyroid cancer) who had undergone metastasectomy at our center during the period 2001–2012. The mean age of the 16 patients (11 men and 5 women) was 62.1 years. The mean interval between completion of successful treatment of the primary tumor and detection of pulmonary metastasis was 21 months (range, 6–56 months). All patients underwent pulmonary resection. The overall 1-year survival rate was 79.4 %, and the 2- to 5-year survival rate was 63.2 %. These rates compare favorably to those in previous reports on resection of pulmonary metastases. When prognostic factors for survival rates were compared, the factors associated with a negative prognosis were a disease-free interval of &lt
    12 months and partial resection of pulmonary metastases. Multivariate analysis did not reveal any prognostic factors associated with negative outcomes. Surgical resection of pulmonary metastases of head and neck cancer might improve outcomes.

    DOI: 10.1007/s12070-014-0799-y

    Scopus

    PubMed

    researchmap

  • Cervical spine osteomyelitis and epidural abscess after chemoradiotherapy for hypopharyngeal carcinoma: a case report. Reviewed

    Ueki Y, Watanabe J, Hashimoto S, Takahashi S

    Case reports in otolaryngology   2014   141307   2014

  • A study on hypopharyngeal carcinoma

    Yushi Ueki, Nao Takahashi, Kunihiro Sato, Sugata Takahashi

    Practica Oto-Rhino-Laryngologica   106 ( 11 )   997 - 1000   2013

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:耳鼻咽喉科臨床学会  

    The clinical data of 56 patients with hypopharyngeal squamous cell carcinoma who were seen between 1991 and 2011 were evaluated at our department. The overall 5-year disease-free survival rate was 43.6%. The survival rates in the patients with stage I (n=3), stage II (n=13), stage III (n=3), stage IV (n=37) disease were 66.7%, 83.8%, 0%, and 31.4%, respectively. Among the patients with stage III/stage IV disease, the survival rate in those who underwent surgery (n=8) was 83.8%, while that in those who underwent concurrent chemoradiotherapy (CCRT) (n=30) was only of 22.3%. The survival rate in patients who underwent adjuvant chemotherapy with S-1 (n=16) was 46.3%, and that in patients who underwent adjuvant chemotherapy without S-1 (n=24) was 20.5%. These results suggest that surgery plays a very important role in the treatment of advanced hypopharyngeal carcinoma and that appropriate adjuvant chemotherapy improves the outcome in these patients.

    DOI: 10.5631/jibirin.106.997

    Scopus

    researchmap

  • 県立中央病院におけるI期II期声門癌の治療成績

    松山 洋, 山崎 恵介, 高橋 姿, 佐藤 邦広, 植木 雄志, 高橋 奈央

    新潟医学会雑誌   126 ( 9 )   505 - 505   2012.9

  • Malignant mucosal melanoma of the head and neck: Results of surgical treatment of 40 cases

    Yuki Saito, Hiroki Mitani, Hiroyuki Yonekawa, Hirofumi Fukushima, Tohru Sasaki, Wataru Shinbashi, Akira Seto, Mutsukazu Kitano, Yuu Koizumi, Yushi Ueki, Ryosuke Kamiyama, Takayuki Kawabata, Aya Ebina, Mitsutaka Adachi, Mariko Ogura, Kazuyoshi Kawabata

    Japanese Journal of Head and Neck Cancer   38 ( 1 )   74 - 79   2012

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Japan Society for Head and Neck Cancer  

    A total of 40 patients with previously untreated mucosal malignant melanoma of the head and neck underwent resection at our hospital between 1980 and 2010. We reviewed the clinical data of these 40 patients. There were 20 men and 20 women, aged 24-79 years (median: 62 years). The site of the primary lesion was the nasal/paranasal cavity in 28 patients, oral cavity in 9 patients, and pharynx in 3 patients. The clinical TNM classification according to the 7th AJCC/UICC was as follows: Stage III, 6 cases
    Stage IVA, 23 cases
    Stage IVB, 9 cases
    T3, 8 cases
    T4a, 23 cases
    and T4b, 9 cases. The 5-year overall survival rate according to the TNM Stage was 100% for Stage III, 46% for Stage IVA, and 11% for Stage IVB. The 5-year overall survival rate (Kaplan-Meier method) was 43%, the 5-year local control rate was 70%, and the disease-free survival rate was 29%. In this study, the TNM classification was well correlated with the clinical outcome
    especially, the prognosis of patients with T4b and N1 was poor. A local recurrence was a therapeutic challenge for the maxillary tuberosity and the pterygoid direction. The subsequent cervical lymph node metastasis rate was high, but neck dissection was considered to have a definitive beneficial effect on survival.

    DOI: 10.5981/jjhnc.38.74

    Scopus

    researchmap

  • A case of difficult-to-diagnose hereditary angioedema

    Yuka Morita, Hideyuki Hanazawa, Yushi Ueki, Sugata Takahashi

    Journal of Otolaryngology of Japan   112 ( 11 )   747 - 751   2009

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Oto-Rhino-Laryngological Society of Japan Inc.  

    Hereditary angioedema (HAE) due to an inherited Cl-inhibitor (CHNH) deficiency causes localized swelling of the oral cavity, pharynx, larynx, and face, that may be life-threatening when the larynx is involved. A 26-year-old woman seen 3 times previously for pharyngeal or laryngeal edema while in her teens, and seen this time for dyspnea was found in computed tomography (CT) to have esophageal edema and pleural effusion. Her C1-INH activity was low, yielding a definitive diagnosis of HAE for her 10-year-plus-disease history. While it is comparatively rare, HAE should be kept in mind in the differential diagnosis of idiopathic edema.

    DOI: 10.3950/jibiinkoka.112.747

    Scopus

    PubMed

    researchmap

  • 両側急性感音難聴を反復したneuro-Sweet病と考えられた1症例

    和田 匡史, 佐藤 斎, 泉 修司, 窪田 和, 植木 雄志, 藤崎 俊之, 高橋 姿

    Audiology Japan   49 ( 3 )   254 - 259   2006.6

     More details

    Language:Japanese   Publisher:(一社)日本聴覚医学会  

    Sweet病は特有の皮疹に発熱,好中球増多を伴う疾患で,なかでも脳炎,髄膜炎などの神経合併症を伴うものはneuro-Sweet病といわれている.今回,感音難聴を合併したneuro-Sweet病と考えられた33歳男性の症例を経験した.本例は髄膜炎症状に随伴,前後して急性感音難聴を左右で計5回繰り返し,明らかに病勢を反映した難聴であった.反復性髄膜炎の所見,頭部MRIでの白質病変,HLA-B54,CW1陽性であることより,neuro-Sweet病と診断された.ステロイド治療により,難聴は改善を認めるも病勢に伴い再発を繰り返した.難聴の原因は自記オージオグラム,SISI検査,ABR,SPECTなどから内耳と中枢の複合病変が考えられた.原因不明の急性感音難聴に髄膜炎などの神経症状を伴う場合には本症も念頭におく必要があると考えられた(著者抄録)

    DOI: 10.4295/audiology.49.254

    CiNii Article

    researchmap

  • Tonsillectomy for recurrent IgA nephropathy following renal transplantation

    Yushi Ueki, Hideo Shinoda, Takashi Kawasaki, Sugata Takahashi

    Practica Oto-Rhino-Laryngologica   99 ( 6 )   467 - 471   2006

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Society of Practical Otolaryngology  

    IgA nephropathy is the most common type of glomerulonephritis, and is characterized by glomerular mesangial proliferation with predominant IgA deposition in the mesangial areas. Long-term observation showed that approximately 40% of patients with IgA nephropathy progress to end-stage renal failure after showing clinical manifestations for 20 years. In recent years, tonsillectomy in IgA nephropathy patients has become prevalent because the treatment has been found efficacious in improving renal survival. We present a case report of IgA nephropathy for which renal transplantation was performed in a 40-year-old man. The patient developed IgA nephropathy that resulted in renal graft dysfunction. To prevent disease progression, he underwent tonsillectomy under general anesthesia. The tonsillar beds were edematous and fragile, and it was very difficult to coagulate the oozing from the tonsillar beds intraoperatively. An argon beam coagulator (ABC) was found to be very useful and safe for bleeding hemostasis. After tonsillectomy, the renal function was stabilized with steroid pulse therapy. For patients progressing to end-stage renal failure, recurrent disease after transplantation remains a clinically important problem. Tonsillectomy may serve as both prophylactic and curative treatment for recurrent IgA nephropathy following renal transplantation.

    DOI: 10.5631/jibirin.99.467

    Scopus

    researchmap

▶ display all

MISC

▶ display all

Presentations

  • 下咽頭癌化学放射線治療における嚥下リハビリテーションの有用性についての検討

    山崎 恵介, 森 香織, 正道 隆介, 富樫 孝文, 植木 雄志, 岡部 隆一, 松山 洋, 本田 耕平, 堀井 新

    頭頸部癌  2018.5 

     More details

    Language:Japanese  

    researchmap

  • 栄養サポートチーム(NST)介入による頭頸部癌化学放射線療法中の栄養状態についての前向き研究

    高橋 剛史, 佐藤 雄一郎, 太田 久幸, 若杉 亮, 植木 雄志, 正道 隆介

    頭頸部癌  2018.5 

     More details

    Language:Japanese  

    researchmap

  • 中・下咽頭表在癌における拡大内視鏡所見と深達度の検討

    岡部 隆一, 松山 洋, 正道 隆介, 富樫 孝文, 植木 雄志, 山崎 恵介, 本田 耕平, 堀井 新

    頭頸部癌  2018.5 

     More details

    Language:Japanese  

    researchmap

  • 頭頸部癌に対するNivolumab投与報告

    松山 洋, 本田 耕平, 山崎 恵介, 岡部 隆一, 植木 雄志, 富樫 孝文, 正道 隆介, 堀井 新

    頭頸部癌  2018.5 

     More details

    Language:Japanese  

    researchmap

  • 当科における再発頭頸部扁平上皮癌のCetuximab併用1次治療不応に対する2次治療の有効性と安全性の検討

    富樫 孝文, 正道 隆介, 植木 雄志, 岡部 隆一, 山崎 恵介, 本田 耕介, 松山 洋, 堀井 新

    頭頸部癌  2018.5 

     More details

    Language:Japanese  

    researchmap

  • 口腔がん細胞におけるPLOD2の発現と機能

    齋藤 憲, 植木 雄志, 近藤 英作

    日本病理学会会誌  2018.4 

     More details

    Language:Japanese  

    researchmap

  • IL-6によるPLOD2転写誘導と口腔がん細胞の浸潤・転移

    植木 雄志, 横山 侑輔, 齋藤 憲, 近藤 英作

    日本病理学会会誌  2018.4 

     More details

    Language:Japanese  

    researchmap

  • 口腔扁平上皮癌におけるPLOD2の発現と細胞移動能との関連

    植木 雄志, 斉藤 憲, 近藤 英作

    日本癌学会総会記事  2017.9 

     More details

    Language:English  

    researchmap

  • PLOD2は口腔がん細胞の移動能を制御する

    齋藤 憲, 植木 雄志, 近藤 英作

    日本癌学会総会記事  2017.9 

     More details

    Language:English  

    researchmap

  • 上咽頭癌化学放射線療法後の補助化学療法

    横山 侑輔, 尾股 丈, 高橋 剛史, 正道 隆介, 富樫 孝文, 植木 雄志, 岡部 隆一, 山崎 恵介, 松山 洋, 堀井 新, 佐藤 雄一郎, 太田 久幸, 富田 雅彦

    頭頸部癌  2017.5 

     More details

    Language:Japanese  

    researchmap

  • 頭頸部扁平上皮癌Stage IVC症例の検討

    尾股 丈, 横山 侑輔, 高橋 剛史, 正道 隆介, 太田 久幸, 富樫 孝文, 植木 雄志, 岡部 隆一, 山崎 恵介, 松山 洋, 堀井 新, 佐藤 雄一郎, 富田 雅彦

    頭頸部癌  2017.5 

     More details

    Language:Japanese  

    researchmap

  • 新潟県の頭頸部扁平上皮癌に対するCCRTの現状 県内多施設共同研究の最終報告

    松山 洋, 山崎 恵介, 岡部 隆一, 植木 雄志, 富樫 孝文, 横山 侑輔, 堀井 新, 佐藤 雄一郎, 正道 隆介, 太田 久幸, 富田 雅彦, 尾股 丈

    頭頸部癌  2017.5 

     More details

    Language:Japanese  

    researchmap

  • 口腔扁平上皮癌細胞におけるPLOD2発現と能動的細胞遊走性との関連性

    植木 雄志, 斉藤 憲, 堀井 新, 近藤 英作

    頭頸部癌  2017.5 

     More details

    Language:Japanese  

    researchmap

  • 新潟大学医歯学総合病院における医科と歯科の連携の試み アンケート結果報告

    山崎 恵介, 富樫 孝文, 植木 雄志, 岡部 隆一, 松山 洋, 船山 昭典, 小田 陽平, 新美 奏恵, 三上 俊彦, 金丸 祥平, 勝見 祐二, 勝良 剛詞, 永田 昌毅, 小林 正治, 堀井 新

    頭頸部癌  2017.5 

     More details

    Language:Japanese  

    researchmap

  • 当科における再発・転移頭頸部扁平上皮癌に対するセツキシマブ併用療法の有効性と問題点の検討

    富樫 孝文, 植木 雄志, 岡部 隆一, 山崎 恵介, 松山 洋

    頭頸部癌  2017.5 

     More details

    Language:Japanese  

    researchmap

  • 口腔扁平上皮癌におけるLysyl Hydroxylase 2の機能解析

    植木 雄志, 齋藤 憲, 近藤 英作

    日本病理学会会誌  2017.3 

     More details

    Language:Japanese  

    researchmap

  • 多様な系統の癌における薬物代謝酵素CYP3A5の発現とその意義

    田坂 杏美, 田中 萌恵, 桑原 一彦, 植木 雄志, 斎藤 憲, 近藤 英作

    日本病理学会会誌  2017.3 

     More details

    Language:Japanese  

    researchmap

  • 頭頸部扁平上皮癌におけるPLOD2の機能解析

    植木 雄志, 斎藤 憲, 堀井 新, 近藤 英作

    新潟県医師会報  2017.2 

     More details

    Language:Japanese  

    researchmap

  • 口腔扁平上皮癌におけるLysyl hydroxylaseの機能

    植木 雄志, 斉藤 憲, 近藤 英作

    日本癌学会総会記事  2016.10 

     More details

    Language:English  

    researchmap

  • 嚥下チームによる食道がん周術期における評価とリハビリについての検討

    齊藤 加奈子, 佐藤 雄一郎, 本間 晶子, 八代 啓子, 中川 悟, 番場 竹生, 太田 久幸, 正道 隆介, 植木 雄志, 森 香織

    嚥下医学  2016.9 

     More details

    Language:Japanese  

    researchmap

  • 口腔扁平上皮癌における水酸化酵素の発現と腫瘍増殖の関連性

    植木 雄志, 斎藤 憲, 近藤 英作

    頭頸部癌  2016.5 

     More details

    Language:Japanese  

    researchmap

  • CDDP+VP-16先行後放射線療法を行った頭頸部小細胞癌の4例

    松山 洋, 山崎 恵介, 岡部 隆一, 植木 雄志, 山崎 洋大, 正道 隆介, 太田 久幸, 高橋 剛史, 尾股 丈, 横山 侑輔, 堀井 新, 富樫 孝文

    頭頸部癌  2016.5 

     More details

    Language:Japanese  

    researchmap

  • 嗅神経芽細胞腫2症例に対する化学療法の経験

    横山 侑輔, 山崎 恵介, 尾股 丈, 高橋 剛史, 太田 久幸, 正道 隆介, 山崎 洋大, 植木 雄志, 岡部 隆一, 富樫 孝文, 松山 洋, 堀井 新

    頭頸部癌  2016.5 

     More details

    Language:Japanese  

    researchmap

  • 喉頭癌T3症例の治療法別治療成績の検討

    山崎 恵介, 横山 侑輔, 植木 雄志, 岡部 隆一, 松山 洋, 堀井 新

    頭頸部癌  2016.5 

     More details

    Language:Japanese  

    researchmap

  • 新潟県内頭頸部癌治療の統一と集約化への動き

    松山 洋, 山崎 恵介, 岡部 隆一, 植木 雄志, 堀井 新, 佐藤 雄一郎, 正道 隆介, 太田 久幸, 富田 雅彦, 富樫 孝文

    日本耳鼻咽喉科学会会報  2016.4 

     More details

    Language:Japanese  

    researchmap

  • 口腔扁平上皮癌における水酸化酵素の発現と腫瘍増殖の関連性

    植木 雄志, 齋藤 憲, 近藤 英作

    日本病理学会会誌  2016.4 

     More details

    Language:Japanese  

    researchmap

  • 頭頸部癌化学放射線治療における栄養状態の変化と治療効果の関係についての検討

    本間 晶子, 大野 恵子, 加藤 つくし, 植木 雄志, 正道 隆介, 佐藤 雄一郎, 齊藤 加奈子, 風間 美幸, 阿部 真紀, 栗田 聡, 齋藤 義之, 松木 淳

    日本病態栄養学会誌  2015.12 

     More details

    Language:Japanese  

    researchmap

  • 唾液腺導管癌の臨床成績と予後因子 多施設共同による141例の検討

    大塚 邦憲, 今西 順久, 多田 雄一郎, 川北 大介, 花澤 豊行, 茶薗 英明, 加納 里志, 清水 顕, 塚原 清彰, 大上 研二, 酒井 昭博, 佐藤 雄一郎, 植木 雄志, 佐藤 由紀子, 小澤 宏之, 小川 郁, 長尾 俊孝

    日本唾液腺学会誌  2015.11 

     More details

    Language:Japanese  

    researchmap

  • 甲状腺手術後のEjnell法による声門開大術施行症例の検討

    山崎 恵介, 植木 雄志, 松山 洋

    日本内分泌・甲状腺外科学会雑誌  2015.9 

     More details

    Language:Japanese  

    researchmap

  • 甲状腺腫瘍にて診断された成人全身型筋線維腫症の1例

    植木 雄志, 佐藤 雄一郎, 森 香織, 正道 隆介, 畠野 宏史, 川崎 隆, 本間 慶一

    日本内分泌・甲状腺外科学会雑誌  2015.9 

     More details

    Language:Japanese  

    researchmap

  • 新潟県における頭頸部癌CCRTのレジメン統一への動き 高用量CDDP+RT

    松山 洋, 岡部 隆一, 富樫 孝文, 正道 隆介, 高橋 姿, 佐藤 雄一郎, 植木 雄志, 山崎 恵介, 富田 雅彦, 山崎 洋大

    頭頸部癌  2015.5 

     More details

    Language:Japanese  

    researchmap

  • 甲状腺手術における術中神経モニタリングの検討

    植木 雄志, 森 香織, 佐藤 雄一郎

    日本耳鼻咽喉科学会会報  2015.4 

     More details

    Language:Japanese  

    researchmap

  • 頭頸部癌治療における経皮内視鏡的胃瘻増設術(PEG)症例の検討

    佐藤 雄一郎, 植木 雄志, 森 香織

    日本耳鼻咽喉科学会会報  2015.4 

     More details

    Language:Japanese  

    researchmap

  • 当科における頭頸部癌に対するセツキシマブの使用経験

    植木 雄志, 正道 隆介, 山崎 洋大, 松山 洋, 高橋 姿

    頭頸部癌  2014.5 

     More details

    Language:Japanese  

    researchmap

  • 当科における上顎洞癌症例の検討

    松山 洋, 正道 隆介, 山崎 洋大, 植木 雄志, 高橋 姿

    頭頸部癌  2014.5 

     More details

    Language:Japanese  

    researchmap

  • 金属歯冠修復物の散乱線による放射線粘膜炎悪化の予防を目的とした散乱線防護デンタルデバイスの効果

    曽我 麻里恵, 勝良 剛詞, 松山 洋, 植木 雄志, 山崎 洋大, 正道 隆介, 林 孝文

    頭頸部癌  2014.5 

     More details

    Language:Japanese  

    researchmap

  • 喉頭に生じた類基底細胞扁平上皮癌の1例

    正道 隆介, 山崎 洋大, 植木 雄志, 松山 洋, 高橋 姿

    頭頸部癌  2014.5 

     More details

    Language:Japanese  

    researchmap

  • 呼吸困難で発症した再発性多発軟骨炎の1例

    森 香織, 石岡 孝二郎, 山崎 洋大, 植木 雄志, 窪田 和, 松山 洋, 高橋 姿

    日本耳鼻咽喉科学会会報  2014.4 

     More details

    Language:Japanese  

    researchmap

  • 下咽頭癌化学放射線療法後に化膿性頸椎炎および硬膜外膿瘍をきたした一例

    植木 雄志, 渡邊 順, 高橋 剛史, 横山 侑輔, 橋本 茂久

    頭頸部癌  2013.5 

     More details

    Language:Japanese  

    researchmap

  • 副鼻腔嚢胞に対する手術治療 術前MRI画像と術中ナビゲーションシステムの有用性

    橋本 茂久, 横山 侑輔, 高橋 剛史, 植木 雄志, 渡邊 順

    日本耳鼻咽喉科学会会報  2013.4 

     More details

    Language:Japanese  

    researchmap

  • 県立中央病院におけるI期II期声門癌の治療成績

    松山 洋, 山崎 恵介, 高橋 姿, 佐藤 邦広, 植木 雄志, 高橋 奈央

    新潟医学会雑誌  2012.9 

     More details

    Language:Japanese  

    researchmap

  • 当科における下咽頭癌症例の検討

    植木 雄志, 高橋 奈央, 佐藤 邦広

    頭頸部癌  2012.5 

     More details

    Language:Japanese  

    researchmap

  • 当科における頬粘膜癌の臨床的検討

    小泉 雄, 三谷 浩樹, 米川 博之, 福島 啓文, 佐々木 徹, 新橋 渉, 瀬戸 陽, 北野 睦三, 斉藤 祐毅, 植木 雄志, 神山 亮介, 川畑 隆之, 蛯名 彩, 川端 一嘉

    頭頸部癌  2011.5 

     More details

    Language:Japanese  

    researchmap

  • 総頸動脈を3/4周取り巻いていたCarcinoma showing thymus-like differentiation(CASTLE)の1例

    北野 睦三, 杉谷 巌, 川畑 隆之, 植木 雄志, 戸田 和寿, 米川 博之, 三谷 浩樹, 元井 紀子, 川端 一嘉

    頭頸部癌  2011.5 

     More details

    Language:Japanese  

    researchmap

  • 手術を中心とした頭頸部粘膜原発悪性黒色腫に対する当科の治療成績

    齊藤 祐毅, 三谷 浩樹, 米川 博之, 福島 啓文, 佐々木 徹, 新橋 渉, 瀬戸 陽, 北野 睦三, 小泉 雄, 植木 雄志, 神山 亮介, 川畑 隆之, 蛯名 彩, 川端 一嘉

    頭頸部癌  2011.5 

     More details

    Language:Japanese  

    researchmap

  • 当科におけるボイスプロステーシス(Provox2)による音声再建

    福島 啓文, 川端 一嘉, 三谷 浩樹, 米川 博之, 佐々木 徹, 新橋 渉, 瀬戸 陽, 北野 睦三, 齊藤 祐毅, 植木 雄志, 神山 亮介, 川畑 隆之, 蛯名 彩, 小倉 真理子, 小柴 茂

    日本耳鼻咽喉科学会会報  2011.4 

     More details

    Language:Japanese  

    researchmap

  • 原発不明頸部転移癌における口蓋扁桃摘出術についての臨床的検討

    新橋 渉, 川端 一嘉, 三谷 浩樹, 米川 博之, 福島 啓文, 佐々木 徹, 瀬戸 陽, 北野 睦三, 斎藤 祐毅, 植木 雄志, 神山 亮介, 川畑 隆之, 蛯名 彩, 小倉 真理子, 小柴 茂

    日本耳鼻咽喉科学会会報  2011.4 

     More details

    Language:Japanese  

    researchmap

  • 当科におけるProvox 2の2期的挿入法について

    福島 啓文, 川端 一嘉, 三谷 浩樹, 米川 博之, 佐々木 徹, 新橋 渉, 瀬戸 陽, 北野 睦三, 齊藤 祐毅, 小泉 雄, 神山 亮介, 川畑 隆之, 植木 雄志, 保富 宗城, 蛯名 彩

    頭頸部癌  2010.5 

     More details

    Language:Japanese  

    researchmap

  • 甲状腺濾胞性病変の術前診断

    植木 雄志, 杉谷 巌, 戸田 和寿, 川端 一嘉, 山田 恵子, 池永 素子

    頭頸部癌  2010.5 

     More details

    Language:Japanese  

    researchmap

  • 腎細胞癌が甲状腺微小浸潤型濾胞癌内に転移した一例

    戸田 和寿, 杉谷 巌, 植木 雄志, 藤本 吉秀, 池永 素子, 山田 恵子, 元井 紀子

    日本内分泌外科学会総会プログラム・抄録集  2010.4 

     More details

    Language:Japanese  

    researchmap

  • 耳下腺原発脂腺癌の1症例

    正道 隆介, 森田 由香, 花澤 秀行, 植木 雄志, 溝江 純悦

    新潟医学会雑誌  2010.3 

     More details

    Language:Japanese  

    researchmap

  • 耳下腺脂腺癌の1症例

    正道 隆介, 植木 雄志, 森田 由香, 花澤 秀行, 溝江 純悦

    頭頸部癌  2009.5 

     More details

    Language:Japanese  

    researchmap

  • 口蓋扁桃原発clear cell carcinoma NOSの1例

    植木 雄志, 森田 由香, 花澤 秀行

    頭頸部癌  2008.5 

     More details

    Language:Japanese  

    researchmap

  • 確定診断に難渋した遺伝性血管浮腫の1例

    森田 由香, 花澤 秀行, 植木 雄志

    日本耳鼻咽喉科学会会報  2008.4 

     More details

    Language:Japanese  

    researchmap

  • 喉頭へ進展した頸部嚢胞状リンパ管腫の成人例

    佐藤 邦広, 植木 雄志, 佐藤 克郎, 高橋 姿

    口腔・咽頭科  2007.8 

     More details

    Language:Japanese  

    researchmap

  • 滲出性中耳炎を合併した特発性肥厚性脳硬膜炎の3症例

    植木 雄志, 藤崎 俊之, 和田 匡史, 佐藤 斎, 高橋 姿

    耳鼻咽喉科臨床 補冊  2005.7 

     More details

    Language:Japanese  

    researchmap

  • 両側急性感音難聴を反復したneuro-Sweet病と考えられた1例

    和田 匡史, 佐藤 斎, 植木 雄志, 泉 修二, 藤崎 俊之, 高橋 姿

    Audiology Japan  2004.10 

     More details

    Language:Japanese  

    researchmap

  • 前庭神経炎と診断後7年目に発見された聴神経腫瘍症例

    植木 雄志, 佐藤 斎, 壁谷 雅之, 和田 匡史, 藤崎 俊之, 高橋 姿

    Audiology Japan  2004.10 

     More details

    Language:Japanese  

    researchmap

  • 扁桃病巣感染症と考えられた移植腎に再発したIgA腎症の1例

    植木 雄志, 篠田 秀夫, 高橋 姿

    口腔・咽頭科  2004.8 

     More details

    Language:Japanese  

    researchmap

  • 前庭水管拡大症の1例

    植木 雄志, 佐藤 斎, 和田 匡史, 藤崎 俊之, 高橋 姿

    日本耳鼻咽喉科学会会報  2004.5 

     More details

    Language:Japanese  

    researchmap

  • 診断に難渋した外リンパ瘻術後の小児心因性めまい・難聴症例

    植木 雄志, 関 聡, 犬飼 賢也, 高橋 紳一郎, 渡辺 一道, 高橋 姿

    Equilibrium Research  2003.10 

     More details

    Language:Japanese  

    researchmap

▶ display all